

Plxnd1-mediated mechanosensing of blood flow controls the caliber of the Dorsal Aorta via the transcription factor Klf2

Jia He¹, Adriana Blazeski^{2,3,4}, Uthayanan Nilanthi⁵, Javier Menéndez¹, Samuel C. Pirani¹, Daniel S. Levic⁷, Michel Bagnat⁷, Manvendra K. Singh^{5,6}, José G Raya⁸, Guillermo García-Cardena^{2,3}, and Jesús Torres-Vázquez^{1*}

¹Department of Cell Biology, NYU Grossman School of Medicine, New York, NY 10016, USA.

²Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA and Harvard Medical School, Boston, MA, USA.

³Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

⁴Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.

⁵Programme in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, 8 College Road, Singapore, 169857

⁶National Heart Research Institute Singapore, National Heart Centre Singapore, 5 Hospital Drive, Singapore, 169609

⁷Department of Cell Biology, Duke University, Durham, NC 27710, USA.

⁸Department of Radiology, New York University School of Medicine, New York, NY 10016, USA.

*Corresponding author. Email: jtorresv@nyulangone.org

Highlights

- Plexin-D1 mechanosensing of blood flow tunes the caliber of the Dorsal Aorta (DA)
- The DA widens without raising endothelial cell numbers, which can change separate from the caliber
- The Kruppel-like transcription factor 2 (KLF2) is a key Plexin-D1 mechano-effector during development
- KLF2 increases endothelial cell size to expand the DA caliber

Keywords

PlexinD1, Klf2, vessel caliber, blood flow, endothelial cells, zebrafish, mouse, artificial human vascular network

SUMMARY

The cardiovascular system generates and responds to mechanical forces. The heartbeat pumps blood through a network of vascular tubes, which adjust their caliber in response to the hemodynamic environment. However, how endothelial cells in the developing vascular system integrate inputs from circulatory forces into signaling pathways to define vessel caliber is poorly understood. Using vertebrate embryos and *in vitro*-assembled microvascular networks of human endothelial cells as models, flow and genetic manipulations, and custom software, we reveal that Plexin-D1, an endothelial Semaphorin receptor critical for angiogenic guidance, employs its mechanosensing activity to serve as a crucial positive regulator of the Dorsal Aorta's (DA) caliber. We also uncover that the flow-responsive transcription factor KLF2 acts as a paramount mechanosensitive effector of Plexin-D1 that enlarges endothelial cells to widen the vessel. These findings illuminate the molecular and cellular mechanisms orchestrating the interplay between cardiovascular development and hemodynamic forces.

INTRODUCTION

Genetic programs and physical forces interact to control signaling pathways, gene expression, and cellular behavior. Their interplay directs embryonic morphogenesis and organ formation, function, and homeostasis. A prominent arena where this coordination plays out is the cardiovascular system, where blood flow forces impact the development of the heart and blood vessels and vice versa. The circulatory function of the cardiovascular system relies on three main factors: the heart's pumping activity, the hierarchical branching of blood vessels, and their ability to adapt their caliber or luminal size to fluid forces and tissue demands[1-5].

According to Poiseuille's law, vascular resistance depends on vessel caliber, length, and blood viscosity. Vascular resistance is the opposition the heart's contractions must overcome to propel blood through vessels and establish circulatory flow. Its value is inversely proportional to the fourth power of the blood vessel's radius. Therefore, the impact of slight alterations in vessel caliber on vascular resistance can be noteworthy. To illustrate, reducing a vessel's luminal radius by ten percent increases its vascular resistance by fifty percent[6].

Vessel caliber influences hemodynamics (blood pressure and tissue perfusion), vascular remodeling, vessel integrity, and the structure and function of the heart. Thus, vessel caliber exerts a global impact on the cardiovascular system's development, performance, and health. Vascular caliber abnormalities lead to cardiovascular diseases that can culminate in disability or death[6-20].

Blood circulation generates mechanical forces that act on the endothelial vascular wall, including circumferential, axial, and shear stress. Circumferential and axial stress depend on intraluminal pressure and act around the vessel's perimeter or length. In contrast, shear stress derives from the friction between blood flow and the endothelial cells (ECs) lining the vessel and occurs parallel to its wall. The magnitude of shear stress primarily depends on the vascular caliber, with secondary influences from the flow rate and the blood's viscosity[6, 21, 22].

ECs express specialized proteins that sense the mechanical forces induced by the circulation. The transformation of these mechanical inputs into intracellular biochemical responses enables blood vessels to adapt to varying hemodynamic conditions using different strategies. These include changes in vessel caliber, the acquisition of an atheroprotective endothelial gene expression profile that suppresses blood clotting and inflammation, and modifications in endothelial barrier function[23-25].

Mammalian Plexin-D1 (Plxnd1 in the zebrafish) is a Semaphorin receptor specific to vertebrates located on the cell surface of various tissues. In the endothelium, this transmembrane protein plays a prominent and evolutionarily conserved role in guiding the stereotypical branching pattern of blood vessels[26-28]. Recent structural analyses and studies with cultured ECs have revealed that Plexin-D1 also functions as a mechanosensor of fluid shear stress[29].

However, the developmental role of the receptor's novel mechanosensing function is unknown. To unveil it, we analyzed the impact of the guidance and mechanosensing activities of Plxnd1, along with blood flow, on the formation of the zebrafish embryonic cardiovascular system. Our studies reveal that Plxnd1 is a crucial component of the endothelial genetic circuit responsible for enabling the Dorsal Aorta (DA), one of the body's largest arteries, to enlarge its caliber in response to increasing circulatory flow forces. Notably, the role of Plxnd1 in regulating DA caliber is distinct from its GAP (GTPase Activating Protein)-mediated guidance function.

Accordingly, *plxnd1* null fish show a decreased DA caliber. *KLF2* (*Krüppel-like Factor 2*) orthologs display fluid shear stress-inducible expression and encode atheroprotective transcription factors with emerging roles in vascular sizing[30-38]. We found that the DA's circulation-induced endothelial upregulation of *klf2* levels is *plxnd1* dependent; see[29]. Furthermore, loss and gain-of-function experiments identify Klf2 as a pivotal Plxnd1 mechano-effector responsible for driving vascular caliber expansion by increasing the size of ECs. Moreover, elevating Klf2 expression in ECs can widen the narrow caliber of the DA in fish that lack blood flow, providing evidence that Klf2 activity *per se* can restore the effects of lack of blood flow on the caliber of DA.

Notably, additional experiments argue that the mechanisms by which the receptor regulates the DA's caliber are similar in fish and mammals. First, murine embryos with endothelial *Plxnd1* deletion also display a narrow DA. Second, studies with perfusable microvascular networks engineered with human endothelial cells show that, like in the zebrafish, circulatory flow increases *KLF2* expression, expands vascular caliber, and enlarges endothelial cells.

Our findings expand our comprehension of the pivotal roles played by Plexin-D1 and KLF2 in cardiovascular development. They also predict the involvement of variants in these genes in diseases promoting vascular caliber abnormalities, such as atherosclerosis, cardiac ischemia, diabetes, hypertension, peripheral artery disease, Raynaud's disease, retinopathy, and systemic sclerosis. Conversely, controlling the activity of these proteins activities could prevent or mitigate these conditions[39-43].

RESULTS

Plxnd1 acts in the endothelium with circulation-dependency as a positive regulator of the DA caliber

In the WT zebrafish embryo, the heart has not yet started beating at 24 hours post-fertilization (hpf), resulting in the absence of circulatory flow at this stage. Soon after, the heartbeat begins, and cardiac output and circulatory flow progressively increase[44-51]. In WTs, the trunk's axial blood vessels respond to increased circulatory flow bi-phasically. They expand up to 48 hpf, narrowing afterward by 72 hpf[44, 45, 52]. To evaluate the influence of circulatory flow and *Plxnd1* on vascular caliber, we manipulated blood flow and *Plxnd1* activities by utilizing recessive alleles. To visualize the vessels, we used the cytosolic endothelial reporter *Tg(fli1:EGFP)^{y1}*[53]. Since the axial vessels are not perfect cylinders, we manually measured their cross-sectional luminal area to establish their caliber. We performed these quantifications before the circulation started (24 hpf) and after it had begun (32, 48, and 72 hpf).

To eliminate blood flow, we used *silent heart (sih)* mutants, which lack the heartbeat due to loss of *tnt2a* (*troponin T type 2a (cardiac)*) expression (*sih^{tc300b}*)[54]. The *tnt2a* gene encodes a critical contractile myofibrillar component selectively expressed in the myocardium and the smooth muscle cells around the heart's outflow tract. Notably, *sih* mutants show properly patterned angiogenic vessels (**Figures S1A, B**) up to 72 hpf and die around one week of age[54-57].

We manipulated *plxnd1* activity using homozygotes of four *plxnd1* alleles or WT embryos with morpholino (MO)-mediated *plxnd1* knockdown (*plxnd1* morphants). We utilized two chemically-induced *plxnd1* alleles to deactivate the receptor's functions completely. The *plxnd1^{Df(Chr08)fs311}* allele is a homozygous-lethal chromosomal deficiency removing *plxnd1* and nearby genes. In contrast, *plxnd1^{fov01b}* harbors a premature stop codon early within the receptor's extracellular Sema domain. Its homozygotes show reduced *plxnd1* mRNA levels, suggesting mutant message degradation and translational suppression[58-60]. To selectively impair the receptor's GAP (GTPase Activating Protein) function essential for its guidance activity, we used genome editing[61] to make *plxnd1^{GAP1}* and *plxnd1^{GAP2}* alleles (**Table S1**) by altering the position of the catalytic and stabilizing Arginine residues at the GAP1 and GAP2 cytosolic tail motifs[26, 62-64], respectively. These four mutants and the morphants display misguided angiogenic vessels (**Figures S1A, C-G**), robust circulation (**Figure S2**; see[58, 59]), and survive to adulthood (except for the *plxnd1^{Df(Chr08)fs311}* fish and *plxnd1* morphants).

Considering the *plxnd1^{Df(Chr08)fs311}* allele's lethal nature[58] and the phenotypic similarities between both *plxnd1^{GAP}* mutants, we primarily relied on the *plxnd1^{fov01b}* and *plxnd1^{GAP1}* alleles for our analyses. Our initial studies revealed that circulatory flow and *plxnd1* might interact differently to dictate the caliber of each axial vessel. Here, we focus on dissecting their role in regulating the DA's caliber.

We observed that the DA calibers of the WT-like siblings (WT-like sibs) of the *plxnd1^{fov01b}*, *plxnd1^{GAP1}*, and *sih* mutants are identical at 24 hpf when circulation has not yet begun (**Figures 1A-C**), indicating that DA lumenogenesis is independent of *plxnd1* and *tnt2a* activities and circulatory flow. Afterward, concurrent with the increasing circulatory flow, we observed that in the mutant's WT-like sibs, the DA caliber gradually expanded to 48 hpf and diminished by 72 hpf (**Figures 1A-C**), consistent with prior findings[52, 65].

The DA caliber of *plxnd1^{GAP1}* mutants adjusts appropriately with changes in blood flow (**Figures 1A, F, G**). Likewise, *plxnd1^{GAP2}* fish display the correct DA caliber in the presence of the circulation (not shown). However, *plxnd1^{fov01b}* mutants exhibit a diminished DA caliber at 32-72 hpf, which expands less up to 48 hpf and subsequently contracts more by 72 hpf compared to their WT-like sibs (**Figures 1B, F, H**). Finally, the DA caliber fails to widen in *sih* mutants, retaining its 24 hpf size (**Figures 1C, F, I**) in alignment with previous observations[66]. Compared to the *sih* mutant, the residual DA caliber modulation of *plxnd1* nulls is consistent with the idea that other flow-responsive regulators of DA caliber are also active during this period.

To investigate the reasons behind the differences in DA caliber between *plxnd1^{fov01b}* and *plxnd1^{GAP}* mutants, we compared *plxnd1^{Df(Chr08)fs311}* mutants and *plxnd1* morphants at 32 hpf, which share the angiogenic misguidance[58, 59] (**Figures S1A, C-G**) and vascular caliber defects of *plxnd1^{fov01b}* fish (**Figure S3**). These observations rule out various potential causes for the reduced DA caliber in *plxnd1^{fov01b}* mutants, including impairment of the receptor's GAP function, misguided angiogenic vessels yielding an abnormal blood flow circuit, linked secondary mutations, or genetic compensation triggered by the mutant transcript's nonsense-mediated RNA decay[67].

To define the role of blood flow in the *plxnd1*-mediated regulation of DA caliber, we eliminated the circulation from *plxnd1^{fov01b}* and *plxnd1^{GAP1}* fish using *sih*; *plxnd1^{GAP1}* and *sih*; *plxnd1^{fov01b}* double mutants. We found that both kinds of double mutants and their single *sih* mutant sibs have identically narrow DA calibers (**Figures 1D-E**), indicating that *plxnd1* regulates the caliber of the DA in a manner dependent on blood circulation.

Lastly, we used a rescue approach to identify which tissue necessitates *plxnd1* to regulate DA caliber. Since *plxnd1* expression includes the endothelium, where it is necessary to guide the vasculature's anatomical

patterning[59, 68-76], and cultured human ECs use *PLXND1* to sense fluid forces[29], we asked if the stable endothelial expression of an HA-tagged form of WT *Plxnd1*[77] via a *Tg(fliiep:2xHA-plxnd1)* transgene suffices to normalize the DA caliber deficit and angiogenic misguidance of *plxnd1^{fov01b}* mutants. Indeed, *plxnd1^{fov01b}; Tg(fliiep:2xHA-plxnd1)*+ fish display proper angiogenic guidance and an expanded DA caliber (**Figures 1J-N**). These findings highlight the endothelial necessity for *plxnd1* in regulating both features.

Plxnd1 promotes the expression of *klf2a* in the DA endothelium in response to blood flow

The *KLF2* (*Krüppel-like factor 2*) genes encode zinc-finger transcription factors expressed in various tissues. Their expression in ECs responds to blood flow, contributing to the atheroprotective adaptation of blood vessels to hemodynamic forces, including maintaining their integrity[30-32, 78-83].

Zebrafish have two *klf2* paralogs, *klf2a* and *klf2b*, with the flow-inducible endothelial expression of *klf2a* being well established [32, 33, 52, 84-89]. To measure the effect of circulatory flow and *plxnd1* activities on *klf2* DA endothelial expression levels with cellular resolution, we used the *klf2a* transcriptional reporter *Tg(klf2a:H2b-EGFP)^{g11}*. In this transgene, a 6 kb *klf2a* promoter fragment drives the expression of a nuclear-targeted histone-EGFP fusion protein[87]. We masked the latter's endothelial signals with the *Tg(kdrl:nls-mCherry)¹⁷³* blood endothelium nuclear reporter[90].

We found that the fluorescence levels of *Tg(klf2a:H2b-EGFP)^{g11}* in the ECs of the DA at 84 hpf are similar between *plxnd1^{GAP1}* mutants and their WT-like sibs (**Figures 2A-B, F**). Notably, embryos of both genotypes exhibit properly sized DA calibers (**Figures 1A, F, G**). In contrast, both *plxnd1^{fov01b}* (**Figures 2C, F**) and *sih* mutants lacking circulation (**Figures 2D, F**) show lower levels of the *klf2a* reporter and reduced DA calibers (**Figures 1B, C, H, I**). In particular, *sih* mutants show the most significant decrease in both aspects. Remarkably, comparing single *sih* mutants and their *plxnd1^{fov01b}; sih* double mutant siblings reveals similar reductions in the endothelial levels of the *klf2a* reporter (**Figures 2E-F**). Hence, *plxnd1* regulates the expression of endothelial *klf2a* in a manner that relies on blood flow. This finding is consistent with the dampened increase in *Klf2* mRNA levels observed in 2D cultures of murine ECs upon *PLXND1* suppression under athero-protective fluid shear stress[29].

Finally, WT embryos show brighter endothelial *klf2a* reporter fluorescence at the DA's floor (**Figure 2A**). This observation fits the prediction of higher shear stress in this ventral region arising from this vessel's dorsal proximity to the rigid notochord and ventral vicinity to the compliant Posterior Cardinal Vein (PCV) and the elastic medium around this vessel[66].

***klf2* activity is necessary for proper DA caliber**

Our data show that *Plxnd1* positively affects DA caliber and endothelial *klf2a* expression. These effects depend on blood circulation and can be distinguished from the receptor's role in guiding blood vessels (**Figures 1-2**), suggesting that *Plxnd1* relies on different downstream molecules to execute its distinct vascular roles.

Various observations highlight *Klf2* as a candidate *Plxnd1* mechano-effector during DA caliber regulation. First, both blood flow (see[32, 33, 52, 84-89]) and *plxnd1* control the endothelial expression of *klf2a* in the DA (**Figure 2**). Second, albeit its transcript's *in situ* visualization remains unpublished, *klf2b* also expresses endothelially[31, 91, 92], suggesting its flow- and *Plxnd1*-responsiveness and functional redundancy with its paralog, *klf2a*. Third, *klf2* activity, like circulatory flow but unlike *plxnd1*, is dispensable for guiding the early anatomical patterning of blood vessels[56, 58, 59, 93]. Finally, accumulating evidence implicates this transcription factor in vessel size regulation. Mammalian and piscine studies have found that mutations in Cerebral Cavernous Malformations (CCM) complex components and their partners induce pathogenic blood vessel dilations with elevated *klf2* endothelial expression, and suppressing *klf2* levels ameliorates these vascular lesions[34, 36, 37, 94-96]. Additionally, *klf2a⁻* and *klf2a⁻; klf2b^{-/+}* fish mutants show axial vessels with progressively smaller outer diameters[35], consistent with the possibility that these animals have reduced vascular calibers.

The hypothesis that *Klf2* is a *Plxnd1* mechano-effector predicts its role as a positive regulator of the DA caliber. To test this notion, we used the *klf2a* (*klf2a^{v616}*)[86] and *klf2b* (*klf2b^{sa43252}*)[97] putative loss-of-function alleles. Indeed, our 72 hpf measurements show that the *klf2a^{v616}* and *klf2b^{sa43252}* single mutants have a reduced DA caliber, with the *klf2* double mutants showing a greater DA caliber deficit (**Figures 3A-E**). Relative to their respective WT-like sibs, the *klf2* double mutants show a greater reduction in DA caliber than *plxnd1^{fov01b}* fish (**Figure 3F**), consistent with the notion that the latter exhibits diminished *klf2* expression (**Figures 2C, F**).

Forced endothelial expression of *klf2a* normalizes the DA caliber of *plxnd1^{fov01b}* and *sih* mutants

If *Klf2* is a *Plxnd1* mechano-effector during DA caliber regulation, it should function in the same tissue as the receptor and compensate for its absence. To test this hypothesis, we made a *Tg(fliiep:klf2a)* transgene to force

the expression of *Klf2a* in ECs. As predicted, this transgene normalizes the DA caliber deficit of *plxnd1^{fov01b}* mutants (**Figures 3G'-I**) while leaving their angiogenic patterning defects intact (**Figures 3G-H**).

To investigate whether artificially increasing *Klf2* expression in ECs enlarges the DA caliber in a circulation-dependent way, we compared the 72 hpf DA caliber of *sih* mutants and their siblings with and without the *Tg(fli:klf2a)* transgene. Despite their lack of blood flow, forced endothelial upregulation of *klf2a* levels expands the DA caliber in *sih* mutants (**Figures 3J'-L**), indicating that blood flow promotes the expression, rather than the function, of *Klf2* to enact vascular caliber expansion. Increasing the expression of *klf2a* did not alter the anatomical pattern of the angiogenic blood vessels in the trunk of *sih* mutants (**Figures 3J-K**).

Remarkably, while artificially expressing *klf2a* in endothelial cells increases the DA caliber in both *plxnd1^{fov01b}* and *sih* mutants to a similar extent (**Figure 3M**), it has no impact on the DA caliber of their WT-like sibs.

Blood flow, *Plxnd1*, and *Klf2* limit EC abundance, but the DA caliber reduction that occurs in their absence is not due to this vessel's hyperplasia

Different endothelial cell mechanisms drive flow-dependent vascular caliber adjustments. An increase in either the number of ECs[88, 98-105] or their area[52, 104, 106, 107] can expand vascular caliber. Conversely, increased EC elongation and alignment to the vessel's axis can narrow its lumen[52].

To understand how *Plxnd1* increases DA caliber in response to circulation at the cellular level, we first manipulated *plxnd1* activities and blood flow. To achieve this goal, we assessed the DA's EC abundance in *plxnd1^{GAP1}*, *plxnd1^{fov01b}*, and *sih* mutants and their WT-like sibs, scoring the embryos before (24 hpf) and after (32, 48, and 84 hpf) the circulation's establishment. We used the *Tg(fli:nEGFP)^{Y7}* pan-endothelial nuclear reporter[100] to quantify EC nuclei within a specified DA segment, posteriorly delimited by the yolk's extension end. We defined the count as DA's ECs per somite (DA's ECs/somite).

We noticed a gradual decrease in EC abundance among the WT-like sibs, indicating that the DA caliber expansion between 24-48 hpf typically happens without increasing the number of DA's ECs (**Figures S4A-C, F**). EC abundance also diminishes in both *plxnd1* mutants, but more slowly (**Figures S4A-B, G-H**). In contrast, EC abundance increases gradually in the DA of *sih* mutants (**Figures S4C, I**). The timing, direction, and magnitude of EC abundance change in these three mutants (**Figures S4A-C**), alongside their distinct patterns of DA caliber evolution (**Figures 1A-C**), argues that the narrow DA caliber of *plxnd1^{fov01b}* and *sih* mutants is not due to this vessel's hyperplasia (the two sections below provide additional support for this notion).

Finally, to determine whether the loss of *klf2* leads increases the DA's EC abundance, as observed upon *plxnd1* inactivation, we compared single (*klf2a* and *klf2b*) and double *klf2* mutants at 84 hpf. The single and double *klf2* mutants display elevated EC abundance, with the latter genotype showing a significantly stronger phenotype. However, EC numbers are higher in *plxnd1^{fov01b}* fish (**Figures S4D-E, F, H, J-L**).

Diminished circulatory shear stress limits the DA's caliber expansion without affecting EC abundance

To further clarify how circulatory forces impact the DA's caliber and EC abundance, we evaluated the impact of lessening circulatory fluid shear stress (by reducing blood viscosity) on these two features over time and its effect on heartbeat frequency (**Figure S5**). Specifically, we lowered the hematocrit by impairing the function of the *gata1a* gene, a critical transcriptional driver of primitive erythrocyte differentiation. Homozygous *gata1a^{m651}* mutants (previously known as *vlad tepes* or *vlt*) lack almost all red blood cells (RBCs)[108] and die between 8-15 dpf[109]. Notably, at 48 hpf (when the DA caliber is the widest in WTs), *gata1a^{m651}* fish have a beating heart with normal morphology, including an atrioventricular canal (AVC) with the proper number of endocardial cells[110], suggesting that the mutant's cardiac function is grossly unaffected by 48 hpf.

Consistent with this notion, we found that *gata1a^{m651}* mutants and their WT-like siblings have identical heartbeat frequencies at 50 hpf (**Figures S5C**). Both genotypes display similar DA calibers at 24 hpf before the heartbeat's onset (**Figure S5A**), indicating that the intravascular entry of RBCs ongoing at this stage is dispensable for DA lumenization and sizing; see[111]. However, in the presence of circulation, the DA of *gata1a^{m651}* fish expands significantly less at 32 and 48 hpf and fails to narrow by 72 hpf. Hence, in *gata1a^{m651}* mutants, the DA caliber is constant from 32-72 hpf. Despite these mutants' DA caliber deficit, their EC abundance is indistinguishable from their WT-like siblings at 24-48 hpf. However, *gata1a^{m651}* mutants display a mild increase in EC abundance by 84 hpf (**Figure S5B**). These findings argue that the *gata1a^{m651}* mutants' reduced circulatory shear stress limits the circulation-induced expansion phase of the DA that culminates at 48 hpf in WTs. Importantly, this deficit is not due to changes in EC abundance. Despite robust blood flow, we note that *plxnd1^{fov01b}* mutants also exhibit limited DA caliber expansion at 32 and 48 hpf.

Plxnd1* increases the DA caliber by promoting the enlargement of ECs through *Klf2

Our research suggests that *Plxnd1* responds to circulatory forces and, via *KLF2*, influences the size, shape, or alignment of ECs, ultimately controlling the DA's caliber. To measure these parameters and differentiate between potential cellular mechanisms, we created the *Vessel Analyzer* app. Using images of the endothelial membrane and a junctional marker, the software performs semi-automated single EC morphometry analysis, extracting data on cell length, width, area, and volume, their 2D and 3D shape (elongation and anisotropy of the inertia moment, respectively), and their alignment to the vessel's axis. Please see the explanatory diagrams of these features in **Figure 4A**.

We used the *TgKl(tjp1a-eGFP)^{pd1252}* knock-in line as the junctional marker for these cellular morphometry analyses. This reporter produces a functional fluorescent Tjp1a fusion protein from the *tjp1a* locus, a *zonula occludens-1* (*zo-1*) ortholog[112]. This gene encodes a bicellular tight junction component of many cell types, including the endothelium[112-116]. To select the junctions in the latter tissue, we masked the *TgKl(tjp1a-eGFP)^{pd1252}* signal with the *Tg(kdrl:mRFP-F)²⁸⁶* endothelial membrane marker[117] (**Figures S6A-A''**).

Our analyses of live *plxnd1*, *klf2*, and *sih* mutants and their WT-like sibs at 84 hpf revealed the following. EC morphometry is unaffected in the adequately sized DA of *plxnd1^{GAP1}* fish, except for a mild, albeit statistically significant, change in cell area (a 15.6% reduction, **Figures S7A-E** and **Table S2**). In contrast, the ECs lining the narrow DA of *plxnd1^{fov01b}* and *klf2* double mutants share considerable and statistically significant reductions in the mean values for length (~23% and ~25%, **Figures 4B-C, S7A**, and **Table S2**), width (~25% and ~33%, **Figures 4D-E, S7B**, and **Table S2**), area (~55% and ~48%, **Figures 4F-G, S7C**, and **Table S2**), and volume (~36% and ~49%, **Figures 4J-K, S7D**, and **Table S2**). However, neither mutant exhibits statistically significant changes in EC shape (**Table S2**). The dispensability of piscine *plxnd1* for EC elongation in response to flow contrasts with findings in 2D cultures of bovine ECs and adult murine aorta in which this morphometric change is receptor-dependent[29]. While this observation might reflect species-specific differences, variables like 2D or 3D endothelial organization, shear stress magnitudes, and exposure periods provide a more likely explanation for this discrepancy.

Notably, the main difference in EC morphometry between *plxnd1^{fov01b}* mutants and *klf2* nulls is the former's EC alignment impairment (from 19.05° in the WT-like sibs to 24.85° in *plxnd1^{fov01b}* fish, a ~30% difference, **Figures 4N-Q, S7E**, and **Table S2**). This phenotype fits the alignment defect observed in the aorta of mice with adult endothelial depletion of *Plxnd1* and cultured Bovine Aortic ECs exposed to laminar fluid shear stress with diminished receptor expression[29]. However, unlike *klf2* null fish, *KLF2* knockdown compromises flow-induced alignment in 2D cultures of human ECs[118], perhaps due to differences between species or, more likely, contrasting experimental conditions.

In the endothelium of the narrow DA of *sih* mutants, the Tjp1a-eGFP fusion protein forms discontinuous junctions with variable thickness and accumulates in large puncta (**Figure S6**). This phenotype is consistent with the notion that circulatory forces promote the maturation of endothelial junctions since similar abnormalities occur in the endothelial adherens junctions of *sih* morphants, as revealed by Vascular Endothelial (VE)-cadherin[119]. While the junctional defects of *sih* mutants prevent the evaluation of EC morphometry, the expectation is that their DA supernumerary ECs are also abnormally small.

Taking into account the unusual cellular morphometry observed in the endothelium of *plxnd1^{fov01b}* and *klf2* (*klf2a*; *klf2b*) null mutants and the capacity of the *Tg(fliiep:2xHA-plxnd1)* and *Tg(fliiep:klf2a)* transgenes to restore the reduced DA caliber in both *plxnd1^{fov01b}* and *sih* mutants (**Figures 1B-C, H-I, K, M-N**, and **Figures 3G'-H', J'-K', I-M**), we investigated the cellular effects on the DA's endothelium of forced *Plxnd1* and *Klf2a* expression in *plxnd1^{fov01b}* and *sih* mutants at 84 hpf.

In *plxnd1^{fov01b}* fish, exogenous expression of *Plxnd1* and *Klf2a* increased the mean values for the ECs' length (28.4% and 22.8%, **Figures 4B, S7F, K** and **Table S2**), width (25.8% and 17.5%; **Figures 4D, S7G, L** and **Table S2**), area (66% and 36%, **Figures 4F, S7H, M** and **Table S2**), and volume (81% and 18.7%, **Figures 4J, S7I, N** and **Table S2**). The data distribution for area and volume also indicates an improvement, with more cells adopting medium to high values and fewer acquiring smaller ones (**Figures 4H-I, L-M**). Neither transgene had statistically significant effects on EC elongation, with augmentations of 0.56% and 3.56% (**Table S2**).

Providing exogenous *Plxnd1* reduced the EC's alignment angle (from 27.14° to 17.72°, a ~30% difference; see **Figures 4N, P, S7J**, and **Table S2**). The *Tg(fliiep:2xHA-plxnd1)* transgene also had a minor but statistically significant effect on the ECs' 3D shape (a 1.3% anisotropy decrease, see **Table S2**). On the other hand, *klf2a* expression improved EC alignment (**Figures 4N, P, S7O**, and **Table S2**, a switch from 23.55° to 18.45°) without reaching statistical significance.

To assess the effectiveness of the two transgenes in rescuing the defective EC morphometry of *plxnd1^{fov01b}* embryos, we used the mean values of WT-like siblings from a cross of *plxnd1^{fov01b/+}* heterozygotes (black label in **Figures 4B, D, F, H, J, L, N, P**) as the benchmark. These assessments suggest that inducing *plxnd1*

expression restores normal EC morphometry in *plxnd1^{fov01b}* fish more effectively than introducing exogenous *klf2a* (dark blue and dark green labels in **Figures 4B, D, F, H, J, L, N, P**). Specifically, the *Tg(fli1p:2xHA-plxnd1)* transgene reinstated all five cellular morphometric characteristics affected in *plxnd1^{fov01b}* mutants to WT-like values, namely the length (~100%), width (~96%), area (~95%), volume (~98%), and alignment (~93%). However, *Tg(fli1p:klf2a)* expression only rescued the four EC morphometry defects shared by *plxnd1^{fov01b}* and *klf2* nulls, namely length (~94%), width (~92%), area (~85%), and volume (76%). **Figure 4R** shows Vessel Analyzer-generated 3D models of DA segments from WT-like sibs, *plxnd1^{fov01b}* fish, and *klf2* (*klf2a*; *klf2b*) double mutants, with the EC junctions projected onto the vessel's luminal surface to illustrate some of the effects of *plxnd1* and *klf2* on EC morphometry.

Significantly, introducing exogenous *Plxnd1* reduced the excess ECs in the DA of *plxnd1^{fov01b}* nulls (**Figure 4S**). In contrast, elevating endothelial *Klf2a* levels did not alleviate the cellular overabundance in *plxnd1^{fov01b}* (**Figure 4T**). and *sih* fish (**Figure 4U**). Nevertheless, forced endothelial expression of *Plxnd1* in *plxnd1^{fov01b}* embryos (**Figures 1M-N**) and of *Klf2a* in *plxnd1^{fov01b}* (**Figures 3H', I, M**) and *sih* mutants (**Figures K', L, M**) expanded their abnormally small DA.

These findings again illustrate that the quantity of ECs in the DA and its caliber can change independently. Moreover, they establish that both *Plxnd1* and *Klf2* control the DA caliber primarily by influencing the size of ECs, not their quantity. Finally, our data also indicates that *Plxnd1*, but not its guidance activity, is necessary for optimal EC alignment.

Engineered microvascular networks (MVNs) made from human ECs respond to circulatory flow by upregulating a reporter of *KLF2* expression, expanding their caliber, and increasing EC size

To determine the evolutionary conservation of the effects of circulatory forces on *KLF2* expression activity, vascular caliber, and EC sizing and bypass the potential confounding effects of developmental changes in cardiac function[44-51] and vascular mural cell investment[65, 86, 120-122], we employed an *in vitro* model.

Specifically, we used ECs carrying a flow-inducible reporter of *KLF2* transcription[123] to construct three-dimensional human MVNs within microfluidic devices and applied flow (or not) using an on-chip microfluidic pump, as in[124] (see also[125, 126]).

To determine the width of vessel lumens, we highlighted the latter by perfusing fluorescent dextran through MVNs. Static MVNs had smaller vessel calibers ($54.5 \pm 2.7 \mu\text{m}$, $n=6$ MVNs) than MVNs cultured under flow ($70.2 \pm 11.5 \mu\text{m}$, $n=5$ MVNs), see **Figures 5A-C**. We found that while MVNs cultured under static (no flow) conditions show minimal expression of *KLF2*-GFP, MVNs exposed to flow express *KLF2*-GFP robustly (**Figures 5D-F**). Notably, as shown in **Figures 5G-I**, ECs in static MVN have smaller areas ($700 \pm 132 \mu\text{m}^2$, $n=651$ cells in 3 MVNs) than ECs in MVNs cultured under flow ($1,344 \pm 397 \mu\text{m}^2$, $n=304$ cells in 3 MVNs).

The differential effects of static and flow conditions in the MVNs parallel those observed in the piscine DA of *sih* mutants and WT, arguing that circulatory forces modulate vascular caliber via similar molecular and cellular effects from fish to humans.

Murine embryos with endothelial *Plxnd1* deficiency display decreased DA caliber

To investigate whether *PLXND1* plays a similar role in regulating the size of the DA in fish and mammals, we selectively deleted *Plxnd1* in the endothelium of mice embryos using the *Tie2^{Cre}* deleter line[127] and the floxed *Plxnd1* (*Plxnd1^{flox}*) allele[71, 74]. Specifically, we harvested control and *Tie2^{Cre/+};Plxnd1^{flox/flox}* embryos from timed matings and made paraffin sections from them, which we processed as follows. We performed Hematoxylin and eosin (H&E) staining (as in[128-130]) or double immunofluorescence for Platelet endothelial cell adhesion molecule (Pecam1 or CD31) and ETS-Related Gene 1 (ERG1) to visualize ECs and their nuclei.

We measured the DA at the cardiac level in cross-sections of E11.25 embryos, when blood flow through the DA is present already[131-135] and *Tie2^{Cre/+};Plxnd1^{flox/flox}* embryos exhibit minimal morphological and structural changes in the outflow tract compared to the controls; see[69, 71]. Compared to the control group, we observed a marked reduction in the luminal area and luminal perimeter of the DA in *Tie2^{Cre/+};Plxnd1^{flox/flox}* (*Plxnd1^{ECKO}*) embryos (**Figure 6**).

Together with our piscine data, these murine findings support the notion that, across vertebrates, *PLXND1* is a positive regulator of the DA's caliber. Furthermore, in light of the results from our MVN experiments, these observations suggest that the receptor exerts its mechanosensing-dependent effects on vascular caliber regulation using evolutionarily conserved molecular and cellular mechanisms.

DISCUSSION

Our piscine results indicate that the novel mechanosensory function of *Plxnd1* is endothelially required to widen the DA's luminal opening in response to increased circulatory friction against the vascular wall. We also uncover that the flow-responsive transcription factor *KLF2* acts as a paramount mechanosensitive effector of *Plxnd1* that enlarges ECs to widen the vessel (**Figure 7**). Furthermore, our data from WT and mutant fish embryos implies that circulatory forces (absent and reduced in *sih* and *gata1a^{m651}* mutants, respectively) and their adequate sensing and transduction (impaired in *plxnd1^{fov01b}* and *klf2* mutants) are critical for correctly sizing this vessel.

Specifically, we uncovered allele-specific effects of *plxnd1* by comparing the DA calibers of mutants with similar angiogenic misguidance phenotypes, namely *plxnd1^{fov01b}*, and *plxnd1^{GAP1}*. Before the onset of blood flow, these mutants and their WT-sibs show equivalent DA sizes. Later, however, when circulation is present, these mutants differ, showing reduced and typical DA calibers, respectively. Consistent with the notion that *Plxnd1* regulates vascular caliber with flow-dependency, we found that *sih* fish and both double *plxnd1;sih* mutants display equivalent DA reduction phenotypes. The smaller caliber of the DA in circulation-deficient *sih* fish compared to *plxnd1* nulls during this vessel's expansion phase, culminating at 48 hpf, highlights the involvement of additional flow-dependent regulators of vascular caliber.

These findings also reveal that the role of *Plxnd1* in DA caliber regulation is distinct from its vascular guidance function, as the former is unaffected by mutations predicted to block its GAP activity, critical for repulsive signaling[63, 64, 136, 137]. Hence, the narrow DA caliber of *plxnd1^{fov01b}* nulls is not secondary to their abnormal circulatory topology, demonstrating *in vivo* that the receptor's two primary functions are genetically separable. This conclusion aligns with the *in vitro* observation that a Plexin-D1 receptor with the ectodomain locked in the closed conformation lacks mechanosensory activity but still triggers cell collapse in response to the repulsive guidance cue *Sema3E*[29].

Consistent with the expected requirement for *Plxnd1* in the endothelium for angiogenic guidance[58, 59, 69-72] and the sensing of circulatory forces[29] that modulate DA sizing, we found that forced expression of the WT receptor in this tissue suffices for restoring angiogenic pathfinding and normalizing the reduced DA caliber of *plxnd1^{fov01b}* nulls.

Our piscine data also establishes that *plxnd1* is necessary for the efficient circulation-dependent transcriptional upregulation of *klf2a*, a piscine ortholog of human *KLF2*, in the DA's ECs; see[32, 33, 52, 84-89]. It is likely that the receptor similarly fosters the endothelial expression of *klf2b* and *klf4*[31, 91, 92], given the reduction of *KLF2* and *KLF4* levels in cultured ECs under laminar fluid shear stress upon *PLXND1* attenuation[29]. How the receptor regulates the expression of these transcription factors is unclear but likely involves indirect mechanisms, given its localization to the cell membrane rather than the nucleus[68, 138-141] (but see[142]). Some potential avenues include MAP3K/MEK5/ERK5 pathway activation[143] and inhibition of CCM (Cerebral Cavernous Malformation) proteins[144], p53[145], and p66shc[146], which promote and antagonize these transcription factors endothelial expression.

Additionally, our findings establish a direct connection between *klf2* expression and DA caliber sizing, position *Klf2* as a *Plxnd1* mechano-effector, and reveal that this transcription factor's activity is independent of blood flow. First, *klf2a* expression is unaffected in *plxnd1^{GAP1}* fish with an adequately sized DA lumen, but it is lower in *plxnd1^{fov01}* null mutants with a reduced DA caliber. This observation implies that other flow-responsive regulators drive residual endothelial *klf2a* expression without *Plxnd1*. Second, *sih* mutants also exhibit reduced *klf2a* levels and decreased DA calibers, and these defects are more robust than those of *plxnd1^{fov01}* nulls. Notably, the reduction in *klf2a* levels and DA caliber is similarly substantial in *sih* and double *plxnd1^{fov01b};sih* mutants, indicating that *Plxnd1* regulates both features in a circulation-dependent way. Third, single *klf2a* and *klf2b* mutants also have a smaller-than-normal DA caliber, which reduces further in *klf2* double mutants, fitting with these genes' expected overlapping functions and the reciprocal paralog's upregulation in the single mutants[93]. Finally, forced endothelial expression of *klf2a* normalizes the DA caliber of both *sih* fish devoid of blood flow and *plxnd1^{fov01b}* mutants with circulation. However, exogenous *klf2a* expression does not rescue the *plxnd1^{fov01b}* mutants' angiogenic misguidance, consistent with the presence of adequately navigating angiogenic vessels in *sih* and *klf2* mutants.

Surprisingly, forced endothelial expression of *klf2a* in WT-like embryos does not affect the DA's caliber. Perhaps the *Tg(fliep:klf2a)* transgene is expressed in the DA at low enough levels to compensate for the mutants' deficits in *klf2* expression without inducing gross gain-of-function phenotypes. Indeed, this transgene's expected equimolar co-expression of farnesylated mCherry is hard to visualize, consistent with limited expression levels. Another explanation is the existence of negative *klf2* autoregulation, in agreement with the semi-redundancy of the piscine *klf2* genes and data from cultured ECs showing that exogenous *KLF2* represses the endogenous gene's expression[30, 93].

At the cellular level, we find that *Plxnd1*, via its *Klf2* mechano-effector, enlarges ECs as blood flow intensifies, thereby widening the DA during the 24-48 hpf period (see[66, 147]). The supporting evidence comes from morphometric analyses after this vessel's expansion phase. First, *plxnd1^{fov01b}* nulls and *klf2* mutants harbor supernumerary ECs with smaller areas and volumes within their reduced DAs. In contrast, *plxnd1^{GAP1}* fish with appropriate DA caliber lack these cellular defects. Second, *sih* mutants without circulation feature a narrow DA with an endothelial surplus. While their junctional maturation defects hinder morphometric analyses based on the *TgKl(tjp1a-eGFP)^{pd1252}* reporter, we deduce that their ECs are abnormally small. Third, forced endothelial expression of the WT receptor rectifies the narrow DA caliber in *plxnd1^{fov01b}* nulls by increasing the area and volume of ECs and decreasing their abundance. However, forced endothelial expression of *klf2a* augments the DA caliber of both *plxnd1^{fov01b}* nulls and *sih* mutants, enlarging the size of ECs without reducing cell numbers. The latter finding indicates that EC enlargement is sufficient for DA expansion and that ECs can change their size without altering their number. Fourth, consistent with the latter notion, in *gata1a^{m651}* mutants with diminished circulatory shear stress, the circulation minimally increases the DA caliber during this vessel's expansion phase. Yet, EC abundance during this period is similar between these mutants and their WT-like sibs.

Furthermore, our data contradicts alternative cellular mechanisms of DA caliber regulation. For instance, the model that the DA expands its caliber from 24-48 hpf through EC addition is inconsistent with our finding that in WTs and the two *plxnd1* mutants analyzed, the DA caliber expands as EC abundance diminishes, albeit this occurs at a slower pace in both mutants. The hypothesis that EC overabundance leads to DA narrowing in *sih*, *klf2*, and *plxnd1^{fov01b}* mutants is irreconcilable with two observations. First, despite the *sih* mutant's rising EC numbers, their narrow DA caliber remains constant. Second, forced endothelial expression of *Klf2a* in *sih* and *plxnd1^{fov01b}* mutants enlarges the footprint and volume of ECs without affecting their abundance, expanding the DA caliber of these fish. Hence, although *sih*, *plxnd1*, and *klf2* mutants display elevated EC abundance, this cellular defect is not responsible for their reduced DA caliber.

However, it is unclear how lack of circulation, loss of *Plxnd1* mechanosensing, and *klf2* inactivation increase the DA's EC abundance. Perhaps the failure to increase EC size somehow enhances cellular proliferation, survival, or both[148, 149]. Alternatively, the flow-dependent specification and extrusion of Hematopoietic Stem Cells (HSCs) at the DA's floor might cause these cells or their EC precursors to remain within the vessel or delay their exit[147, 150].

Our piscine and murine findings indicate that endothelial *PLXND1* is a positive regulator of the DA's caliber across vertebrates. Additionally, using engineered MVNs made of human ECs carrying a transcriptional reporter of *KLF2* expression within a microfluidic chip, we found that flow induces statistically significant increases in the expression of the *KLF2*-GFP-reporter, vessel diameter, and EC size when compared to MVNs cultured under static (no flow) conditions. Remarkably, the differential effects of flow and static conditions in the MVNs parallel those observed in the piscine DA of WT embryos and *sih* mutants devoid of blood flow. The results from our experiments with vertebrate models and MVNs argue that circulatory forces exert similar molecular and cellular effects from fish to mammals. They also suggest that the receptor's mechanosensing-dependent effects on vascular caliber regulation rely on evolutionarily conserved molecular and cellular mechanisms.

Although this study centers on the role of *Plxnd1*-mediated mechanosensing in regulating the DA caliber, our data suggests that the receptor might also determine the size of the trunk's axial vein, the PCV. However, the relationship between *Plxnd1* and flow is different in this case. Given its widespread endothelial expression[59, 68-70, 92, 151-157], *plxnd1* might exert a broad influence on the caliber of other vessels, including arteries, veins, capillaries with high shear stress levels (found in skeletal muscles[158] and the kidney's glomeruli[159]), and lymphatic vessels[75, 76, 154]). In agreement with the notion that the effects of *Plxnd1* on vascular caliber may be contextual, the cerebral vessels widen after transient brain infarction in mice with endothelial *Plxnd1* depletion[155].

Rescue experiments of *klf2* double mutant fish indicate that endothelial *klf2* activity also prevents the extrusion of ventricular cardiomyocytes in the heart[93], forecasting that *Plxnd1*-mediated mechanosensing may promote myocardial wall integrity by ensuring the abundance of this mechano-effector in ECs. Moreover, the central role of fluid shear stress in endocardial, venous, and lymphatic valve formation suggests that the *Plxnd1*-mediated detection of this mechanical stimuli regulates valvulogenesis across the cardiovascular system. Fittingly, both the receptor[68, 69, 71, 74, 92, 154, 160] and *Klf2* express in the piscine and mammalian endocardium and orchestrate the morphogenesis of cardiac valve leaflets in fish and mice[161-164].

The bi-functional nature of the receptor prompts consideration of its activities' regulation. While the flexibility of the *Plxnd1* ectodomain seems necessary for mechanosensing[29], our findings imply that its intracellular GAP activity, key for guidance, is dispensable for sensing or interpreting circulatory forces. We envision that *Plxnd1* carries out its distinct roles within separate sub-cellular compartments, with apical-junctional (see[29]) and

basolateral (see[165, 166]) receptor pools mediating mechanosensing and guidance, respectively. This model implies that the proximal effectors and modulators of these distinct functions show a similar pattern of distribution or activation.

We anticipate that *Plxnd1* harbors specific and shared molecular determinants of its two activities. Accordingly, mutations in this receptor might exert selective or pervasive functional effects. Human *PLXND1* variants are associated with congenital cardiac abnormalities, including defects in how blood vessels connect to the heart, often leading to the carriers' fetal demise[167-170]. These abnormalities fit the phenotypes of mice with global or endothelial removal of *Plxnd1* and are attributable, at least partly, to the loss of its guidance function[28, 69-71, 74, 154, 171]. However, some of these variants might additionally affect mechanosensing. Perhaps other *PLXND1* variants[172] selectively alter the ability of the receptor to detect blood flow forces. These considerations invite using model systems to uncover the molecular determinants of the receptor's functions, verify the pathogenicity of *PLXND1* variants, and define the specificity of their functional impact.


The novel role of *PLXND1* and *KLF2* as vascular caliber regulators suggests that variants in these genes could contribute to diseases involving reduced vascular calibers, myocardial ischemia[173, 174], peripheral artery disease[175], atherosclerosis[29], hypertension[176], diabetes[177], and glaucoma[178]. Thus, increasing the expression or activity of Plexin D1 and KLF2 might therapeutically enhance the blood flow in individuals afflicted by these conditions and in patients with congenital heart defects suffering from impaired cardiac blood flow. This strategy could also potentiate some cancer treatments by improving the delivery of anti-tumor drugs and vascular-disrupting reagents[179, 180].

Limitations of the study


(1) Our animal experiments employ receptor alleles that specifically lack guidance activity (this study) or are null[58, 59, 71], devoid of both guidance and mechanosensing functions. (2) Rescue experiments with 2D EC cultures argue that locking the receptor in its closed conformation (by introducing an intramolecular disulfide bond between the receptor's first and ninth extracellular domains) abrogates its mechanosensing activity[29]. However, we have not tested the ability of such a form to rescue the DA caliber deficits of fish or mice lacking the endogenous receptor. (3) Besides eliminating cardiac contractility and RBCs, it is difficult to precisely manipulate piscine blood flow forces for an extended period[49, 50, 181, 182]. This challenge also applies to mice embryos. (3) The circulation deficiency of *sih* mutant fish is an extreme condition with potential secondary effects[183, 184]. However, as demonstrated by the *gata1a* mutants, reduced circulatory shear stress induces qualitatively similar effects on DA caliber. (4) The murine heart's outflow tract arises as a single tube, the truncus arteriosus, that later septates into the aorta and the pulmonary artery. The septation fails in *Tie2^{Cre/+};Plxnd1^{fllox/fllox}* embryos and mice are born with persistent truncus arteriosus. Some *Tie2^{Cre/+};Plxnd1^{fllox/fllox}* embryos also develop ventricular septal defects. These congenital heart defects increase blood flow into the lungs, reducing irrigation elsewhere[71, 74]. However, it is unclear when these circulatory changes begin and whether they affect DA size. (5) We have not evaluated the impact of manipulating *PLXND1* and *KLF2* levels in MVNs under static or flow conditions. We highlight that the coherency of our zebrafish, mouse, and engineered MVN made of human ECs data fully supports our conclusions.

FIGURES

Figure 1. Endothelial *Plxnd1* controls the caliber of the aorta in a circulation-dependent fashion. (A-E) Comparisons of aortic caliber (luminal area of aortic cross-sections) at 24, 32, 48, and 72 hpf in fixed siblings (sibs) of various genotypes. Statistical measures are as follows. The dots represent means. The error bars denote the standard deviation (SD). Significance levels as * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$; unpaired two-tailed Student's *t*-test. **(A)** Comparison of WT-like sibs (grey) vs. *plxnd1*^{GAP1} mutants (cyan). WT-like sibs group: WT and both single (*plxnd1*^{GAP1/+} and *sih*^{tc300b/+}) and double (*plxnd1*^{GAP1/+}; *sih*^{tc300b/+}) heterozygotes. *plxnd1*^{GAP1} mutant group: *plxnd1*^{GAP1} and *plxnd1*^{GAP1}; *sih*^{tc300b/+}. WT-like sibs per stage: 24 hpf (n = 10), 32 hpf (n = 11), 48 hpf (n = 11), 72 hpf (n = 10). *plxnd1*^{GAP1} mutants per stage: 24 hpf (n = 19), 32 hpf (n = 12), 48 hpf (n = 19), 72 hpf (n = 24). Significance levels per stage: 24 hpf ($p=0.4936$), 32 hpf ($p=0.2120$), 48 hpf ($p=0.6335$), 72 hpf ($p=0.1840$). **(B)** Comparison of WT-like sibs (grey) vs. *plxnd1*^{fov01b} mutants (navy blue). WT-like sibs group: WT and both single (*plxnd1*^{fov01b/+} and *sih*^{tc300b/+}) and double (*plxnd1*^{fov01b/+}; *sih*^{tc300b/+}) heterozygotes. *plxnd1*^{fov01b} mutant group: *plxnd1*^{fov01b} and *plxnd1*^{fov01b}; *sih*^{tc300b/+}. WT-like sibs per stage: 24 hpf (n = 12), 32 hpf (n = 11), 48 hpf (n = 11), 72 hpf (n = 13). *plxnd1*^{fov01b} mutants per stage: 24 hpf (n = 15), 32 hpf (n = 10), 48 hpf (n = 15), 72 hpf (n = 16). Significance levels per stage: 24 hpf ($p=0.2145$), 32 hpf ($p<0.0001$), 48 hpf ($p<0.0001$), 72 hpf ($p<0.0001$). **(C)** Comparison of WT-like sibs (grey) vs. *sih*^{tc300b} mutants (orange). WT-like sibs group: WT and both single (*sih*^{tc300b/+} and *plxnd1*^{fov01b/+}) and double (*plxnd1*^{fov01b/+}; *sih*^{tc300b/+} and *sih*^{tc300b/+}; *plxnd1*^{GAP1/+}) heterozygotes. *sih*^{tc300b} mutant group: *sih*^{tc300b} homozygotes alone and with *plxnd1* heterozygosity (*sih*^{tc300b}; *plxnd1*^{GAP1/+} and *sih*^{tc300b}; *plxnd1*^{fov01b/+}). WT-like sibs per stage: 24 hpf (n = 12), 32 hpf (n = 22), 48 hpf (n = 27), 72 hpf (n = 26). *sih*^{tc300b} mutants per stage: 24 hpf (n = 13), 32 hpf (n = 21), 48 hpf (n = 27), 72 hpf (n = 22). Significance levels per stage: 24 hpf ($p=0.3077$), 32 hpf ($p<0.0001$), 48 hpf ($p<0.0001$), 72 hpf ($p<0.0001$). **(D)** Comparison of *sih*^{tc300b} sibs (orange) vs. *plxnd1*^{GAP1}; *sih*^{tc300b} double mutants (light green). *sih*^{tc300b} sibs group: *sih*^{tc300b} and *sih*^{tc300b}; *plxnd1*^{GAP1/+}. The genotype of the double mutant group is self-explanatory. *sih*^{tc300b} sibs per stage: 24 hpf (n = 7), 32 hpf (n = 11), 48 hpf (n = 10), 72 hpf (n = 12). *plxnd1*^{GAP1}; *sih*^{tc300b} double mutants per stage: 24 hpf (n = 15), 32 hpf (n = 7), 48 hpf (n = 15), 72 hpf (n = 15). Significance levels per stage: 24 hpf ($p=0.4236$), 32 hpf ($p=0.8098$), 48 hpf ($p=0.7940$), 72 hpf ($p=0.0419$). **(E)** Comparison of *sih*^{tc300b} sibs vs. *plxnd1*^{fov01b}; *sih*^{tc300b} double mutants (dark green). *sih*^{tc300b} sibs group: *sih*^{tc300b} and *sih*^{tc300b}; *plxnd1*^{fov01b/+}. The genotype of the double mutant group is self-explanatory. *sih*^{tc300b} sibs per stage: 24 hpf (n = 5), 32 hpf (n = 10), 48 hpf (n = 17), 72 hpf (n = 15). *plxnd1*^{fov01b}; *sih*^{tc300b} double mutants per stage: 24 hpf (n = 6), 32 hpf (n = 12), 48 hpf (n = 14), 72 hpf (n = 25). Significance levels per stage are as follows: 24 hpf ($p=0.2434$), 32 hpf ($p=0.9735$), 48 hpf ($p=0.1637$), 72 hpf ($p=0.0221$).



(F-I) Representative DA and PCV cross-sections from live 48 hpf embryos reconstructed from confocal microscopy images. Endothelium (green), *Tg(fli1:EGFP)^{Y1}*. The dorsal side is up, and the left side is left. (F) WT. The scale bar (horizontal white line) is 15 μm . (G) *plxnd1^{GAP1}* mutant. (H) *plxnd1^{fov01b}* mutant. (I) *sih^{tc300b}* mutant.



(J-N) Forced endothelial expression of HA-tagged Plxnd1 rescues the angiogenic misguidance and the reduced DA caliber of *plxnd1^{fov01b}* mutants. (J-M) Lateral views of the trunk of fixed sibling *plxnd1^{fov01b}* mutants without (J-K) or with (L-M) the *Tg(fli1p:2xHA-plxnd1)* transgene at 32 hpf (J-J', L-L') and live embryos 72 hpf (K, M). The dorsal side is up, and the anterior side is left. HA immunostaining, green. Endothelium (red), *Tg(kdr1:mCherry)²⁰⁶* reporter [185]. The scale bar (horizontal white line) is 40 μm (J', K). (N) Quantification of DA caliber in sibling *plxnd1^{fov01b}* mutants at 72 hpf as a function of the absence (-) or presence (+) of the *Tg(fli1p:2xHA-plxnd1)* transgene. Statistical measures. The dots represent individual data points. The horizontal lines represent the means. The error bars denote the SD. Significance level, *** $p < 0.001$, unpaired two-tailed Student's *t*-test.




Figure 2. *Plxnd1*, but not its GAP activity, promotes the DA's endothelial expression of the *klf2a* transcriptional reporter *Tg(klf2a:H2b-EGFP)^{tg11}* in a circulation-dependent manner. (A-F) Data from live embryos of various genotypes at 84 hpf. (A-E') Lateral views of the trunk. The dorsal side is up, and the anterior side is left. Endothelial nuclear signals from the *Tg(klf2a:H2b-EGFP)^{tg11}* reporter scaled by intensity (A, B, C, D, E); intensity scale in (A). Endothelial nuclear signals (red) from the *Tg(kdr1:nls-mCherry)^{y173}* reporter, used to mask the *Tg(klf2a:H2b-EGFP)^{tg11}* signals with tissue specificity (A', B', C', D', E'). (A-A') WT sib. The scale bar (horizontal white line) is 40 μ m (A'). (B-B') *plxnd1^{GAP1}* mutant. (C-C') *plxnd1^{fov01b}* mutant. (D-D') *sih^{tc300b}* mutant. (E-E') *plxnd1^{fov01b}; sih^{tc300b}* double mutant. (F) Graph of live DA's EC fluorescence intensity of the *Tg(klf2a:H2b-EGFP)^{tg11}* reporter. Statistical measures are as follows. Dots represent individual data points (color-coded to indicate siblings). The long and thick horizontal lines represent the means. The short and thin horizontal lines represent the error bars (SD). Significance levels as NS > 0.05, *p \leq 0.05, **p \leq 0.01, *p \leq 0.001. Unpaired two-tailed Student's *t*-test. Comparison of WT-like sibs (n = 7; WTs and *plxnd1^{GAP1/+}*) vs. *plxnd1^{GAP1}* mutants (n = 7), gray dots, p=0.7045. Comparison of WT-like sibs (n = 18; WTs and *plxnd1^{fov01b/+}*) vs. *plxnd1^{fov01b}* mutants (n = 18), blue dots, p<0.0001. Comparison of WT-like sibs (n = 9; WTs and *sih^{tc300b/+}*) vs. *sih^{tc300b}* mutants (n = 12), green dots, p<0.0001. Comparison of WT-like sibs (n = 9; WTs, *plxnd1^{fov01b/+}*, *sih^{tc300b/+}*, and *plxnd1^{fov01b/+}; sih^{tc300b/+}*) vs. *plxnd1^{fov01b}* mutants (n = 8; *plxnd1^{fov01b}* and *plxnd1^{fov01b}; sih^{tc300b/+}*), *plxnd1^{fov01b}* mutants (n = 8; *sih^{tc300b}* and *plxnd1^{fov01b/+}; sih^{tc300b}*), and *plxnd1^{fov01b}; sih^{tc300b}* double mutants (n = 8), orange dots, p<0.0001. WT-like sibs vs. *plxnd1^{fov01b}*, p<0.0001. WT-like sibs vs. *sih^{tc300b}*, p<0.0001. WT-like sibs vs. *plxnd1^{fov01b}; sih^{tc300b}* double mutants, p<0.0001. *plxnd1^{fov01b}* vs. *sih^{tc300b}*, p<0.0001. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b}; sih^{tc300b}* double mutants, p<0.0001. *sih^{tc300b}* vs. *plxnd1^{fov01b}; sih^{tc300b}* double mutants, p=0.2592.**




Figure 3. Loss of *klf2* genes reduces the DA caliber, while forced endothelial expression of *klf2a* expands the DA caliber of both *plxnd1^{fov01b}* and *sih* mutants without affecting angiogenic patterning. (A-F) Images (A-D) and quantifications (E-F) from 72 hpf fixed embryos. (A-D) Lateral views of the trunk's vasculature. The dorsal side is up, and the anterior side is left. Endothelium (green), *Tg(fli1:EGFP)^{y1}*. (A) WT-like sib. The scale bar (horizontal white line) is 40 μ m long. (B) *klf2a^{y616}* mutant. (C) *klf2b^{sa43252}* mutant. (D) *klf2* double mutant (*klf2a^{y616}*; *klf2b^{sa43252}*). (G-M) Images (G-K') and quantifications (I, L-M) from 72-76 hpf live embryos. (G-H') Endothelium (green), *Tg(fli1a:lfeactGAP)^{mu240}*. (J-K') Endothelium (green), *Tg(fli1:EGFP)^{y1}*. (G-H, J-K) Lateral views of the trunk's vasculature. The dorsal side is up, and the anterior side is left. (G, J) The scale bar (horizontal white line) is 40 μ m long. (G', H', J', K') Representative DA and PCV cross-sections reconstructed from confocal microscopy images. The dorsal side is up, and the left side is left. White asterisks mark the DA. Yellow asterisks mark the PCV. (G, G') *plxnd1^{fov01b}* mutant. (H, H') *plxnd1^{fov01b}*; *Tg(fliiep:klf2a)* mutant. (J, J') *sih^{tc300b}* mutant. (K, K') *sih^{tc300b}*; *Tg(fliiep:klf2a)* mutant. (G', J') The scale bar (horizontal white line) is 15 μ m long. (E-F, I, L-M) Quantifications. Statistical measures are as follows. The dots represent individual data points. The horizontal lines represent the means. The error bars denote the SD. Significance levels as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, Unpaired two-tailed Student's *t*-test. (E) DA caliber in WT-like sibs (homozygous WT and heterozygotes for the *klf2a^{y616}* or *klf2b^{sa43252}* alleles), *klf2a^{y616}* and *klf2b^{sa43252}* single and double mutants. WT-like sibs (homozygous WT and heterozygotes for the *klf2a^{y616}* or *klf2b^{sa43252}* alleles) (n = 13). *klf2a^{y616}* (n = 10). *klf2b^{sa43252}* (n = 10). *klf2a^{y616}* and *klf2b^{sa43252}* double mutants (n = 17). WT-like sib vs. *klf2a^{y616}*, $p < 0.0001$. WT-like sib vs. *klf2b^{sa43252}*, $p < 0.0001$. WT-like sib vs. *klf2a^{y616}*; *klf2b^{sa43252}*, $p < 0.0001$. *klf2a^{y616}* vs. *klf2b^{sa43252}*, $p = 0.9787$. *klf2a^{y616}* vs. *klf2a^{y616}*; *klf2b^{sa43252}*, $p < 0.0001$. *klf2b^{sa43252}* vs. *klf2a^{y616}*; *klf2b^{sa43252}*, $p < 0.0001$. (F) Normalized DA calibers in the *klf2* double and *plxnd1^{fov01b}* single mutants and in the latter's WT-like sibs (homozygous WT and *plxnd1^{fov01b/+}* heterozygotes). WT-like sib (n = 13) vs. *klf2a^{y616}*; *klf2b^{sa43252}* (n = 17), $p < 0.0001$. WT-like sib (n = 11) vs. *plxnd1^{fov01b}* (n = 10), $p < 0.0001$. (I) DA caliber in WT-like sibs (homozygous WT and *plxnd1^{fov01b/+}* heterozygotes) and *plxnd1^{fov01b}* mutants with and without the *Tg(fliiep:klf2a)* transgene. *plxnd1^{fov01b}* (n = 10) vs. *plxnd1^{fov01b}*; *Tg(fliiep:klf2a)* (n = 10), $p = 0.0044$. (L) DA calibers in *sih^{tc300b}* mutants with and without the *Tg(fliiep:klf2a)* transgene. *sih^{tc300b}* (n = 8) vs. *sih^{tc300b}*; *Tg(fliiep:klf2a)* (n = 10), $p = 0.0002$. (M) Normalized DA calibers in *plxnd1^{fov01b}* and *sih^{tc300b}* mutants and in the WT-like sibs of the former (*plxnd1^{fov01b/+}* heterozygotes).




Figure 4. Plxnd1 expands the DA caliber by enlarging the area of ECs via Klf2. (A) Explanatory diagrams. On the top left is the location of basal and luminal surfaces in the DA, with the vessel's longitudinal axis (yellow dashed line) projecting out the page at an angle. The other illustrations define EC morphometric parameters within a DA oriented horizontally. Length (white line): distance along the vessel's lumen connecting the two points within the cell's perimeter (shown in green) furthest apart along the vessel's axis. Width (white line): the transversal length connecting the two most distant points within the cell's perimeter (outlined in green) along the vessel's lumen. Area (green surface): measured at the vessel's luminal side. Volume (green form with shadowing): calculated by integrating the cell's height between the luminal and basal areas (to ease comprehension, the DA has been rotated 90° around the vessel's longitudinal axis compared to the other illustrations of EC morphometry). Alignment angle or angle with the vessel's axis (θ): measured as the angle between the cell's minor principal axis of rotation (black continuous line) and the vessel's longitudinal axis (yellow dashed line). See **METHOD DETAILS (Zebrafish: imaging and quantification of EC morphometry with the Vessel Analyzer app). Comparisons of EC morphometry in live embryos.** (B, D, F, H, J, L, N, P) Black: WT-like sibs vs. *plxnd1^{fov01b}*. Blue: *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*. Green: *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*. (C, E, G, I, K, M, O, Q) Orange: WT-like sibs vs. *klf2a⁻; klf2b⁻*, $p=0.0031$. (B-C) Graphs of mean EC length values. (B) Comparison of WT-like sibs vs. *plxnd1^{fov01b}*, $p=0.0018$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, $p=0.0003$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*, $p=0.0018$. (C) WT-like sibs vs. *klf2a⁻; klf2b⁻*, $p=0.0031$. (D-E) Graphs of mean EC width values. (D) Comparison of WT-like sibs vs. *plxnd1^{fov01b}*, $p=0.0094$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, $p=0.0041$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*, $p=0.0016$. (E) WT-like sibs vs. *klf2a⁻; klf2b⁻*, $p=0.0231$. (F-G) Graphs of mean EC area values. (F) Comparison of WT-like sibs vs. *plxnd1^{fov01b}*, $p=0.0001$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, $p=0.0003$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*, $p=0.0001$. (G) WT-like sibs vs. *klf2a⁻; klf2b⁻*, $p=0.0003$. (H-I) Histograms of EC area distribution. X axis, EC area. Y axis, percentage of ECs scored. (J-K) Graphs of mean EC volume values. (J) Comparison of WT-like sibs vs. *plxnd1^{fov01b}*, $p=0.0022$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, $p=0.0026$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*, $p=0.0180$. (K) WT-like sibs vs. *klf2a⁻; klf2b⁻*, $p=0.0009$. (L-M) Histogram of EC volume distribution. X axis, EC volume. Y axis, percentage of the ECs scored. (N-O) Graphs of the mean EC alignment angles. (N) Comparison of WT-like sibs vs. *plxnd1^{fov01b}*, $p=0.0128$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, $p=0.0039$. *plxnd1^{fov01b}* vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*, $p=0.1613$. (O) WT-like sibs vs. *klf2a⁻; klf2b⁻*, $p=0.6077$. (P-Q) Quarter-polar histogram plots of EC alignment angle distribution (binned in 15° intervals). R axis, percentage of scored ECs. Theta axis, 0-90°. (B-Q) For all genotypes, $n = 4$, except for *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, in which $n = 5$. (R) 3D vessel models with EC junctions made by the Vessel Analyzer App. Top panel, WT-like sib. Middle panel, *plxnd1^{fov01b}*. Bottom panel, *klf2a⁻; klf2b⁻* double mutants. (S-U) Graphs comparing the DA's EC abundance per somite at 84 hpf in sibling embryos. (S) *plxnd1^{fov01b/+}* ($n = 5$) vs. *plxnd1^{fov01b/+} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, ($n = 7$); $p=0.3387$. *plxnd1^{fov01b}* ($n = 7$) vs. *plxnd1^{fov01b} + Plxnd1 (Tg(fliiep:2xHA-plxnd1))*, ($n = 8$); $p=0.0003$. (T) *plxnd1^{fov01b/+}* ($n = 7$) vs. *plxnd1^{fov01b/+} + Klf2a (Tg(fliiep:klf2a))*, ($n = 10$); $p=0.3387$. *plxnd1^{fov01b}* ($n = 7$) vs. *plxnd1^{fov01b} + Klf2a (Tg(fliiep:klf2a))*, ($n = 10$); $p=0.0503$. (U) *sih^{tc300b}* ($n = 10$) vs. *sih^{tc300b} + Klf2a (Tg(fliiep:klf2a))*, ($n = 10$); $p=0.2429$. Statistical measures are as follows. (B-G, J-K, N-O) Dots denote means from individual larvae. (S-U) Dots denote the average EC abundance values of individual larvae. (B-G, J-K, N-O, S-U) Long and thick horizontal lines represent the means. Short and thin horizontal lines, error bars (SD). Significance levels as * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$), unpaired two-tailed Student's *t*-test.

Figure 5. Circulatory flow promotes the activation of a reporter of *KLF2* expression, caliber expansion of vessels, and EC enlargement in MVNs. Representative confocal images (maximum intensity projections) of vascular lumens illuminated with fluorescent dextran (**A-B**; red, scale bar is 100 μm), *KLF2*-GFP expression (**D-E**; green, scale bar is 50 μm), and vascular endothelial-cadherin immunofluorescence (VE-cadherin, gray) and DAPI staining (blue) outlining EC perimeters and marking cell nuclei (**G-H**; scale bar is 50 μm) in MVNs under static (**A, D, G**) and flow (**B, E, H**) conditions. (**C**) Graph comparing the average luminal diameter of MVNs cultured under static and flow conditions. $p=0.0097$ for flow (5 MVNs) vs. static (6 MVNs). (**F**) Graph comparing *KLF2*-GFP fluorescence levels, expressed as the percentage of GFP-positive imaging area of MVNs cultured under static and flow conditions. $p=0.0386$ for flow (3 MVNs) vs. static (3 MVNs) conditions. (**I**) Superplot graph^[186] compares individual ECs' areas in MVNs cultured under static and flow conditions. $p=0.0280$ for flow (3 MVNs, 651 cells) vs. static (3 MVNs, 304 cells) conditions. Statistical measures are as follows. Larger circles denote means (color-coded per MVN). Small dots represent individual EC measurements (color-coded per MVN). Long horizontal lines represent the means of each MVN. Short horizontal lines, error bars (SD). Significance levels as * $p\leq 0.05$, ** $p\leq 0.01$, *** $p\leq 0.001$, unpaired one-tailed Student's *t*-test.




Figure 6. Endothelial *Plxnd1* is necessary for proper DA caliber in murine embryos. (A-B) Hematoxylin and eosin (H&E) stained paraffin sections from the cardiac level, showing the DA of E11.25 control (A) and *Plxnd1*^{ECKO} (B) embryos. (C-D) Cardiac level sections (scale bars, 100 μ m) of E11.25 control (C) and *Plxnd1*^{ECKO} (D) embryos immunofluorescently stained to visualize the DA's expression of Pecam1 (red) and ERG1 (green) and counterstained with the DNA stain DAPI (blue) to highlight nuclei. (A-D) Scale bars, 100 μ m. (E-F) Graphs of the DA's luminal area (E) and luminal perimeter (F) in H&E stained control (n=4, black) and *Plxnd1*^{ECKO} embryo sections (n=5, blue). We measured both the right and the left DA of each embryo. Statistical measures are as follows. We report the values as means \pm SEM (standard error of the mean). Significant differences, * p <0.05; unpaired two-tailed Student's *t*-test. The two genotypes show statistically significant differences in both area (p =0.0186) and perimeter (p =0.0111).





Figure 7. Model of circulation-dependent DA caliber regulation by Plxnd1 via Klf2.



SUPPLEMENTARY FIGURES

Figure S1. Angiogenic patterning in WT, *sih* and *plxnd1* mutants, and *plxnd1* morphants at 32 hpf. Lateral views of the trunk's vasculature in fixed, immune-fluorescently stained embryos of various genotypes. Endothelium (green), *Tg(fli1:EGFP)^{y1}*. The dorsal side is up, and the anterior side is left. (A) WT. The scale bar (horizontal white line) is 40 μ m units long. (B) *sih^{tc300b}* mutant. (C) *plxnd1^{Df(Chr8)fs311}* mutant. (D) *plxnd1^{fov01b}* mutant. (E) *plxnd1^{GAP1}* mutant. (F) *plxnd1^{GAP2}* mutant. (G) *plxnd1* morphant.




Figure S2. Red blood cell circulation in WT and *plxnd1* mutants at 84 hpf. Lateral views of the trunk's vasculature in live embryos. Endothelium (green), *Tg(fli1:EGFP)^{y1}* reporter (A, B, C, D, E). Erythrocytes (magenta), *Tg(gata1a:dsRed)^{sd2}* reporter [187] (A-E'). The fast-moving erythrocytes within the axial vessels appear as closely packed diagonal red lines. The dorsal side is up, and the anterior side is left. (A-A') WT. The scale bar (horizontal white line) is 60 μ m long. (B-B') *plxnd1^{fov01b}*. The erythrocytes occupy a narrower luminal space within the DA and PCV. (C-C') *plxnd1^{GAP1}* mutant. (D-D') *plxnd1^{GAP2}* mutant.




Figure S3. Both *plxnd1^{fov01b}* and *plxnd1^{Df(Chr08)fs31}* mutants and *plxnd1* morphants show reduced DA calibers at 32 hpf. (A-C') DA (luminal area of DA cross-sections) in fixed siblings (sibs) of different genotypes. Statistical measures are as follows. The grey dots represent individual data points. The long and thick horizontal lines represent the means. The short and thin horizontal lines represent the error bars (SD). Significance levels as * $p \leq 0.05$, ** $p \leq 0.01$, * $p \leq 0.001$, two-tailed unpaired Student's *t*-test. (A, B, C) Comparison of absolute values. (A', B', C') Comparison of normalized DA calibers. (A-A') Comparison of WT-like sibs vs. *plxnd1^{fov01b}* mutants. WT-like sibs group (n = 11): WTs and both single (*plxnd1^{fov01b}/+* and *sih^{tc300b}/+*) and double (*plxnd1^{fov01b}/+*; *sih^{tc300b}/+*) heterozygotes. *plxnd1^{fov01b}* mutants (n = 10): *plxnd1^{fov01b}* and *sih^{tc300b}/+*; *plxnd1^{fov01b}*. $p < 0.0001$. (B-B') Comparison of WT-like sibs vs. *plxnd1^{Df(Chr08)fs31}* mutants. WT-like sibs group (n = 9): WTs and both single (*plxnd1^{Df(Chr08)fs31}/+* and *sih^{tc300b}/+*) and double (*plxnd1^{Df(Chr08)fs31}/+*; *sih^{tc300b}/+*) heterozygotes. *plxnd1^{Df(Chr08)fs31}* mutants (n = 11): *plxnd1^{Df(Chr08)fs31}* and *sih^{tc300b}/+*; *plxnd1^{Df(Chr08)fs31}*. $p < 0.0001$. (C-C') Comparison of WT vs. WT (*plxnd1* MO); $p = X$. WT group (n = 11): Un-injected WTs. WT (*plxnd1* MO) group (n = 10): WTs with *plxnd1* MO injection. $p = 0.0009$.**




Figure S4. Comparison of EC abundance in the DA of live *plxnd1*, *sih*, and *klf2* mutants and their sibs. (A-C) Graphs comparing the DA's EC abundance over time (at 24, 32, 48, and 84 hpf) in *plxnd1*^{GAP1} (A), *plxnd1*^{fov01b} (B), and *sih*^{tc300b} mutants and their WT-like sibs (homozygous WT and heterozygotes). Data is color-coded by genotype. Statistical measures are as follows: Dots denote each genotype's means. Horizontal lines, error bars (SD). Significance levels as *p<0.05, **p<0.01, ***p<0.001; unpaired two-tailed Student's *t*-test. (A) WT-like sibs (grey) vs. *plxnd1*^{GAP1} mutants (cyan) comparisons are as follows. 24 hpf: WT-like sibs (n=12) vs. *plxnd1*^{fov01b} (n=14), p=0.6883. 32 hpf: WT-like sibs (n=10) vs. *plxnd1*^{fov01b} (n=9), p=0.8054. 48 hpf: WT-like sibs (n=9) vs. *plxnd1*^{fov01b} (n=9), p=0.2542. 84 hpf: WT-like sibs (n=12) vs. *plxnd1*^{fov01b} (n=12), p<0.0001. (B) WT-like sibs (grey) vs. *plxnd1*^{fov01b} (navy blue) comparisons are as follows. 24 hpf: WT-like sibs (n=11) vs. *plxnd1*^{fov01b} (n=15), p=0.0002. 32 hpf: WT-like sibs (n=13) vs. *plxnd1*^{fov01b} (n=14), p=0.7443. 48 hpf: WT-like sibs (n=9) vs. *plxnd1*^{fov01b} (n=9), p<0.0001. 84 hpf: WT-like sibs (n=13) vs. *plxnd1*^{fov01b} (n=14), p<0.0001. (C) WT-like sibs (grey) vs. *sih*^{tc300b} (orange) comparisons are as follows. 24 hpf: WT-like sibs (n=7) vs. *sih*^{tc300b} (n=7), p=0.7043. 32 hpf: WT-like sibs (n=10) vs. *sih*^{tc300b} (n=11), p=0.0012. 48 hpf: WT-like sibs (n=10) vs. *sih*^{tc300b} (n=10), p=0.0001. 84 hpf: WT-like sibs (n=10) vs. *sih*^{tc300b} (n=14), p<0.0001. (D-E) Graphs comparing the DA's EC abundance (D) and the normalized (using the WT-like sibs as reference) DA's EC abundance (E) at 84 hpf in both single (*klf2a*⁻ and *klf2b*⁻) and double *klf2* (*klf2a*⁻; *klf2b*⁻) mutants, *plxnd1*^{fov01b} mutants, and their WT-like sibs (homozygous WT and single heterozygotes for both the single and double mutants). Statistical measures are as follows. Dots denote individual data points. Long horizontal lines represent the means. Short horizontal lines, error bars (SD). Significance levels as *p<0.05, **p<0.01, ***p<0.001, unpaired two-tailed Student's *t*-test. WT-like sibs (n=35) vs. *klf2a*⁻ (n=7), p<0.0001. WT-like sibs (n=35) vs. *klf2b*⁻ (n=7), p<0.0001. WT-like sibs (n=35) vs. *klf2a*⁻; *klf2b*⁻ (n=13), p<0.0001. *klf2a*⁻ (n=7) vs. *klf2b*⁻ (n=7), p=0.3244. *klf2a*⁻ (n=7) vs. *klf2a*⁻; *klf2b*⁻ (n=13), p=0.0012. *klf2b*⁻ (n=7) vs. *klf2a*⁻; *klf2b*⁻ (n=13), p=0.0005. WT-like sibs (n=13) vs. *plxnd1*^{fov01b} (n=14), p<0.0001. (F-L) Representative lateral views of the trunk vasculature in live 84 hpf embryos of the indicated genotypes. Endothelial nuclei (green), *Tg(fli:nEGFP)*^{y7} reporter [100]. The dorsal side is up, and the anterior side is left. The scale bar (horizontal white line) represents 40 μm (F).




Figure S5. RBC-deficient *gata1a^{m651}* mutants show reduced DA caliber but normal EC abundance and heartbeat frequency during this vessel's circulation-induced expansion phase. (A-C) Comparisons of WT-like sibs (WTs and *gata1a^{m651/+}* heterozygotes) vs. *gata1a^{m651}* mutants. Significance levels as NS>0.05, *p<0.05, **p<0.01, *p<0.001; unpaired two-tailed Student's *t*-test. (A) Aortic caliber in fixed embryos (luminal area of aortic cross-sections) at different time points (24, 32, 48, and 72 hpf). The dots represent means per genotype, and the short horizontal lines denote error bars (SD). WT-like sibs (grey) vs. *gata1a^{m651}* mutants (magenta). WT-like sibs per stage: 24 hpf (n = 13), 32 hpf (n = 10), 48 hpf (n = 11), 72 hpf (n = 12). *gata1a^{m651}* mutants per stage: 24 hpf (n = 10), 32 hpf (n = 12), 48 hpf (n = 9), 72 hpf (n = 14). Significance levels per stage: 24 hpf (p=0.8284), 32 hpf (p<0.0001), 48 hpf (p<0.0001), 72 hpf (p=0.0126). (B) aEC abundance at different time points (24, 32, 48, and 84 hpf) in live embryos. The dots represent means per genotype, and the short horizontal lines denote error bars (SD). WT-like sibs (grey) vs. *gata1a^{m651}* mutants (magenta). WT-like sibs per stage: 24 hpf (n = 12), 32 hpf (n = 7), 48 hpf (n = 12), 72 hpf (n = 7). *gata1a^{m651}* mutants per stage: 24 hpf (n = 5), 32 hpf (n = 7), 48 hpf (n = 8), 72 hpf (n = 6). Significance levels per stage: 24 hpf (p=0.4110), 32 hpf (p<0.0001), 48 hpf (p<0.0001), 72 hpf (p=0.0126). (C) Heart rate at 50 hpf. Gray dots represent data from individual embryos, the wide horizontal lines are means, and the short horizontal lines represent error bars (SD). WT-like sibs: n=7. *gata1a^{m651}*: n=7. Significance level: p=0.7220.**




Figure S6. Endothelial junction defects in *sih* mutants. The panels show lateral views of the trunk's axial vessels from live 84 hpf embryos. The dorsal side is up, and the anterior side is left. **(A, B)** Endothelial membranes (red), *Tg(kdrl:mRFP-F)^{y286}*. **(A', B')** Endothelial Tjp1a-eGFP (+) tight junctions (green), *TgKl(tjp1a-eGFP)^{pd1252}*. **(A'', B'')** Both reporters. **(A-A'')** WT-like sib. The scale bar (horizontal white line) is 40 μ m. **(B-B'')** *sih^{tc300b}* mutant. Note that the DA shows tight junctions of variable widths and accumulation of the Tjp1a-eGFP fusion protein in large puncta (white arrowheads).





Figure S7. *Plxnd1* expands the DA caliber by enlarging the area of ECs via *Klf2*. (A-O) Superplot graphs[186] compare the EC morphometry of live mutants' and their WT-like sibs: length (A, F, K), width (B, G, L), area (C, H, M), volume (D, I, N), and alignment angle (E, J, O). The mean values for all these genotypes are also in Figure 4, except for *plxnd1*^{GAP1} and their WT-like sibs, shown here only (see below). Statistical measures are as follows. Large circles denote means color-coded for each larva. Small dots represent data from individual ECs, color-coded for each larvae. The long, thick horizontal lines represent the means. Short and thin horizontal lines, error bars (SD). Significance levels as *p≤0.05, **p≤0.01, ***p≤0.001, unpaired two-tailed Student's *t*-test. (A-E) Comparisons of *plxnd1*^{GAP1}, *plxnd1*^{fov01b}, and *klf2* (*klf2a*; *klf2b*) double mutants against their WT-like sibs (homozygous WTs for the three mutants and heterozygotes for the *plxnd1*^{GAP1} and *plxnd1*^{fov01} alleles). WT-like sibs (4 embryos, 104 cells) vs. *plxnd1*^{GAP1} (4 embryos, 105 cells), purple label: (A) p=0.6718, (B) p=0.4635, (C) p=0.0355, (D) p=0.6753, (E) p=0.4348. WT-like sibs (4 embryos, 101 cells) vs. *plxnd1*^{fov01b} (4 embryos, 162 cells), black label: (A) p=0.0018, (B) p=0.0094, (C) p=0.0001, (D) p=0.0022, (E) p=0.0128. WT-like sibs (4 embryos, 103 cells) vs. *klf2* double mutants (4 embryos, 148 cells), orange label: (A) p=0.0031, (B) p=0.0231, (C) p=0.0003, (D) p=0.0009, (E) p=0.6077. (F-J) Comparisons of *plxnd1*^{fov01b} (4 embryos, 170 cells) vs. *plxnd1*^{fov01b} + *Plxnd1* (*Tg(flietp:2xHA-plxnd1)*) (5 embryos, 133), blue label: (F) p=0.0003, (G) p=0.0041, (H) p=0.0003, (I) p=0.0026, (J) p=0.0039. (K-O) Comparisons of *plxnd1*^{fov01b} (4 embryos, 129 cells) and *plxnd1*^{fov01b} + *Klf2a* (*Tg(flietp:klf2a)*) (4 embryos, 97 cells), green label: (K) p=0.0018, (L) p=0.0016, (M) p=0.0001, (N) p=0.0180, (O) p=0.1613.



SUPPLEMENTARY TABLES

Table S1. Molecular description of the *plxnd1*^{GAP} mutant alleles.

Allele	aa sequence	Genomic sequence (top strand)	Targeting gRNA
WT	PKL M LRR	CCCAA A CTGATGCTGCGGCGCACC	<i>plxnd1</i> -gRNA-01 (J.T-V. lab vector #1204)
<i>plxnd1</i> ^{GAP1}	PKL M LRR	CCCAA A CTGATGCTGCGGCGCACC	
WT	LPLRF W VN	ttagtCTGCCGCTGCG C TCT G GGTGAACATC	<i>plxnd1</i> -gRNA-02 (J.T-V. lab vector #1281)
		ttagtCTG C CGCTG C GCTTCTGGGTGAACATC	<i>plxnd1</i> -gRNA-03 (J.T-V. lab vector #1280)
<i>plxnd1</i> ^{GAP2}	LPR S FWVN	ttagtCTGCC C AGAA G CTTCTGGGTGAACATC	

Amino acid (aa) sequences: The arginine residues (R1439, R1440 in the GAP1 motif, and R1725 in the GAP2 motif) corresponding to the WT protein are bolded. In the mutant sequences, the deleted amino acids are in light gray font, and the amino acid substitutions are in red font. **Genomic sequences:** Exonic sequences are in uppercase, while intronic sequences are in lowercase. The gRNA target sites (WT allele) are in blue font. *plxnd1*-gRNA-01: 5'-GGTGC**CG**CGCAGCATCAGTT-3'. *plxnd1*-gRNA-02: 5'-GGAGTCTGCCGCTGCGCTTC-3'. *plxnd1*-gRNA-03: 5'-GGGTT**C**ACCCAGAA**G**CGCAG-3'. The protospacer adjacent motif (PAM) is in pink font. The two bases between which Cas9 cleaves have yellow highlighting. In the mutant sequences, base deletions are in light gray font, and base substitutions appear in red font. See **KEY RESOURCE TABLE**.

Table S2. Comparisons of EC morphometry values (means of means) between genotypes at 84 hpf.

The EC area, length, width, volume, and alignment values are the same as those in **Figures 4** and **S7**. The blue text denotes significant differences ($p < 0.05$) between the compared genotypes, with red text denoting a reduction and green text indicating an increase.

Genotype	Area	Length	Width	Volume	Alignment	Elongation	Anisotropy
WT-like sibling	570.9042	57.4228563	13.52507299	3088.75992	18.29706311	4.66004987	0.515681817
<i>plxnd1^{GAP1}</i>	481.8047	55.5983168	15.07921961	3261.53504	16.14612128	4.95099718	0.51680339
Change in the mutants relative to their WT-like siblings	-15.60%	-3.17%	11.49%	5.59%	-11.75%	6.24%	0.217%
Significant difference?	Yes	No	No	No	No	No	No
WT-like sibling	588.2728	58.9735646	15.3137922	3578.415676	17.36141433	4.276900014	0.506070924
<i>klf2a⁻; klf2b⁻</i>	302.9163	44.0969995	10.25194428	1831.799189	18.91026647	5.855259582	0.501811588
Change in the mutants relative to their WT-like siblings	-48.5%	-25.22%	-33.05%	-48.80%	8.92%	36.90%	0.84%
Significant difference?	Yes	Yes	Yes	Yes	No	No	No
WT-like sibling	484.2919	58.2685662	11.8435857	3613.485465	19.05682426	5.33869558	0.500334762
<i>plxnd1^{fov01b}</i>	267.0656	44.7820458	8.820555865	2311.152563	24.85766216	5.617951178	0.467789694
Change in the mutants relative to their WT-like siblings	-55.14%	-23.14%	-25.52%	-36.04%	30.43%	5.23%	-6.50%
Significant difference?	Yes	Yes	Yes	Yes	Yes	No	No
<i>plxnd1^{fov01b}</i>	292.9983429	43.54898616	9.953547016	2046.073068	27.1428956	4.847833027	0.467040799
<i>plxnd1^{fov01b}; Tg(fliedp:2xHA-plxnd1)</i>	486.521478	55.9177572	12.5234932	3701.82259	17.7295894	4.87520298	0.49369876
Change in the rescued mutants relative to their mutant sib	66.04%	28.40%	25.81%	80.92%	-34.68%	0.56%	5.70%
Significant difference?	Yes	Yes	Yes	Yes	Yes	No	Yes
Change in the rescued mutants relative to WT-like siblings (from a separate cross)	0.46%	-4.03%	5.74%	2.44%	-6.96%	-8.68%	-1.32%
<i>plxnd1^{fov01b}</i>	301.0293343	44.57717603	9.253509187	2310.417664	25.00469927	5.059885931	0.473341904
<i>plxnd1^{fov01b}; Tg(fliedp:klf2a)</i>	409.643219	54.75179986	10.87178166	2742.713085	16.65272388	5.240449467	0.512587129
Change in the rescued mutants relative to their mutant sib	36.08%	22.82%	17.48%	18.71%	-33.40%	3.56%	8.29%
Significant difference?	Yes	Yes	Yes	Yes	No	No	No
Change in the rescued mutants relative to WT-like siblings (from a separate cross)	-15.41%	-6.03%	-8.20%	-24.09%	-12.61%	-1.84%	2.44%

ACKNOWLEDGMENTS

Funding. The NIH's NHLBI grant 1R01HL161090-01A1 (to JTV) supported the murine, MVNs, and zebrafish studies in the MKS, GGC, and JTV labs. Grants from the Singapore Ministry of Health's NMRC (MOH-OFIRG18nov-0036) and the Singapore Ministry of Education (MOE-T2EP30121-0025) also funded the work in the MKS lab. The NIH grants R21HL152367 and T32EB016652 (to GG-C and AB) sponsored the experiments with MVNs, too. The NIH grant 1R01DK1321120 (to MB) sponsored the generation of *TgKl(tjp1a-eGFP)^{pd1252}*.

Reagents. Fixed embryos: Sarah Childs (*plxnd1^{Df(Chr08)fs311}*; *Tg(kdrl:GFP)^{la116}* and their WT-sibs)[97]. Fish lines: Brant Weinstein and Dan Castranova (*Tg(kdrl:mRFP-F)^{y286}*)[117], Neil Chi and Julien Vermot (*Tg(klf2a:H2b-EGFP)^{g11}*)[87], Amber N. Stratman (*klf2a^{y616}*)[86]. Michel Bagnat (*TgKl(tjp1a-eGFP)^{pd1252}*)[112], the Zebrafish International Resource Center/ZIRC (*gata1a^{m651}*, *klf2b^{sa43252}*, and *sih^{tc300b}*). Vectors: Chi-Bin Chien and Koichi Kawakami (pCS2FA-transposase, pDestToI2CG2, and p3E-polyA,)[188], Nathan Lawson (p5E-fliep)[189], Salim Abdelilah-Seyfried (pME-klf2a)[94], and Xingxu Huang (pST1374-NLS-flag-linker-Cas9; Addgene plasmid #44758)[190]. **Microscopy.** Zebrafish confocal imaging was done at the NYU Grossman School of Medicine's Microscopy Laboratory (partially supported by the NIH's NCI grant P30CA016087) using a Leica SP8 confocal system (supported by the NIH's NCRG grant 1S10RR024708). We thank Michael Cammer for imaging guidance. **Scientific advice.** We thank our colleagues E. Jane Albert Hubbard, Holger Knaut (and members of his lab), Ruth Lehman, Jeremy F. Nance, Niels Ringstad, Agnel Sfeir, Hyung Don Ryoo, and Jessica E. Treisman for useful suggestions.

AUTHOR CONTRIBUTIONS

AB: Investigation, data curation, formal analysis, methodology, visualization, writing – review and editing. **DSL:** Resources, writing – review and editing. **GGC:** Supervision, writing -original draft, writing – review, and editing. **JH:** Resources, data curation, formal analysis, investigation, methodology, visualization, writing -original draft, Writing – review and editing. **JGR:** Software, writing -original draft, writing – review, and editing. **JTV:** Conceptualization, funding acquisition, project administration, supervision, resources, methodology, writing- original draft, writing – review and editing. **JM:** Resources, writing – review and editing. **MB:** Resources, writing – review and editing. **MKS:** Formal analysis, writing -original draft, writing – review and editing. **SCP:** Resources, writing – review and editing. **UT:** Data curation, formal analysis, methodology, visualization.

METHODS

KEY RESOURCE TABLE

REAGENT OR RESOURCE	SOURCE	IDENTIFIER
Antibodies (mouse studies)		
Alexa Flour goat anti-Rabbit IgG (H+L) 647	Thermo Fisher Scientific	Catalog #A-21245
Alexa Flour goat anti-Rat IgG (H+L) 488	Thermo Fisher Scientific	Catalog #A-11006
Rabbit monoclonal anti-ERG1	Abcam	Catalog #ab92513
Rat monoclonal anti-Pecam1 (CD31; mouse)	eBioscience Thermo Fisher Scientific	Catalog #14-0311-82
Antibodies (MVs)		
Mouse anti-Human CD144	BD Pharminogen	Catalog #555661
Alexa Flour goat anti-Mouse IgG (H+L) 647	Thermo Fisher Scientific	Catalog #A32728
Antibodies (zebrafish studies)		
Alexa Fluor 488 goat anti-chicken	Invitrogen ThermoFisher Scientific	Catalog #A11039
Alexa Fluor 647 donkey anti-rat	Invitrogen ThermoFisher Scientific	Catalog #A78947
Chicken anti-GFP	Invitrogen ThermoFisher Scientific	Catalog #A10262
Cy3 donkey anti-sheep	Jackson ImmunoResearch LABORATORIES INC	#713-165-147
Rat anti-HA	Sigma-Aldrich	#11867423001
Sheep anti-mCherry	Yamaguchi et al.[191]	Custom-made (from Holger Knaut)
Chemicals (mouse)		
DAPI	Vector Laboratories	Catalog #H-1200-10
Eosin	Leica	Catalog #3801606
Hematoxylin	Leica	Catalog #3801570
Chemicals (zebrafish)		
1-Phenyl-2-thiourea (PTU)	Sigma-Aldrich	Catalog #P7629
4% PFA in PBS, pH 7.5	Santa Cruz Biotechnology	Catalog #sc-281692
AquaPor HR GTAC Agarose, low melt	national diagnostics	Catalog #EC-205
Bovine Serum Albumin (BSA)	Sigma-Aldrich	Catalog #A8022
Instant Ocean sea salt for aquariums	That Fish Place	Catalog #198140
Methylene Blue	Sigma-Aldrich	Catalog #122965-43-9
Tricaine	Fisher Scientific	Catalog #AC118000100
Tricaine	Sigma-Aldrich	Catalog #A5040-25g
Tween 20	Sigma-Aldrich	Catalog #P1379
Reagents (MVs)		
4% Paraformaldehyde Solution	Thermo Fisher Scientific	Catalog #J19943.K2
DAPI Solution (1 mg/mL)	Thermo Fisher Scientific	Catalog #62248
Dow Sylgard 184 Silicone Encapsulant	Ellsworth Adhesives	Catalog #184 SIL ELAST KIT 0.5KG
Fibrinogen from Bovine Plasma	Sigma-Aldrich	Catalog #F8630
Fluorescent Dextran (Texas Red, 70,000 MW)	Thermo Fisher Scientific	Catalog #D1864
Goat Serum	Gibco	Catalog #16210072
Human Lung Fibroblasts	Lonza	Catalog #CC-2512
Phosphate Buffered Saline (PBS)	Thermo Fisher Scientific	Catalog #J61196.AP
Thrombin from Bovine Plasma	Sigma-Aldrich	Catalog #T4648
Triton X-100	Fisher Scientific	Catalog #BP151-100
VasculLife VEGF medium	Lifeline Cell Technology	Catalog #LL-0003
Commercial reagents or kits (zebrafish)		
BioReady Taq DNA Polymerase	Bulldog Bio	Catalog #BSAX050
Cas9 protein from <i>S. pyogenes</i> with NLS	PNA Bio	Catalog #CP01
Gateway LR Clonase Enzyme mix	Thermo Fisher Scientific	Catalog #11791019
MEGashortscript T7 kit	ThermoFisher Scientific	Catalog #AM1354
Phusion High-Fidelity DNA polymerase	ThermoFisher Scientific	Catalog #F30L
pCR8/GW/TOPO TA Cloning Kit (pCR8/GW/TOPO TA vector)	Thermo Fisher Scientific	Catalog #K250020
TOPO TA Cloning Dual Promoter kit (pCRII-TOPO vector)	ThermoFisher Scientific	Catalog #450640
TOPO TA Cloning kit (pCR2.1-TOPO vector)	ThermoFisher Scientific	Catalog #450641
T7 RNA polymerase	New England Biolabs	Catalog #M0251S
Other (zebrafish)		

AquaPor HR GTAC Agarose	national diagnostics	Catalog #EC-205
Cover Glass, 25x25 mm Square #1½	Corning	Catalog #2850-25
Fisherbrand Frosted Microscope Slides	fisher scientific	Catalog #12-550-400
Petri plastic dish, 35 mm	Falcon	Catalog #353001
Experimental models: organisms/strains		
Mouse: <i>Plxnd1^{flox/flox}</i>	Zhang et al.[71] and Sandireddy et al.[74]	RRID:IMSR_JAX:018319
Mouse: <i>Tie2^{Cre/+}</i>	Kisanuki et al.[127]	RRID:IMSR_JAX:008863
Zebrafish: <i>gata1a^{m651}</i>	Lyons et al.[108].	ZDB-ALT-980203-521; see https://zfin.org/
Zebrafish: <i>klf2a^{y616}</i>	Stratman et al.[86]	ZDB-ALT-210728-6; see https://zfin.org/
Zebrafish: <i>klf2b^{sa43252}</i>	Kettleborough et al.[97]	ZDB-ALT-160601-8832; see https://zfin.org/
Zebrafish: <i>plxnd1^{Df(Chr08)fs311}</i>	Childs et al.[97]; see Torres-Vázquez et al.[97]	ZDB-ALT-010621-4; see https://zfin.org/
Zebrafish: <i>plxnd1^{fov01b}</i>	Childs et al.[97]; see Torres-Vázquez et al.[97]	ZDB-ALT-010621-6; see https://zfin.org/
Zebrafish: <i>plxnd1^{GAP1}</i>	This paper	<i>plxnd1^{skt25}</i>
Zebrafish: <i>plxnd1^{GAP2}</i>	This paper	<i>plxnd1^{skt26}</i>
Zebrafish: <i>sihc^{300b}</i>	Sehnert et al.[54]	ZDB-FISH-150901-1548; see https://zfin.org/
Zebrafish: <i>Tg(fli1:EGFP)^{y1}</i>	Lawson and Weinstein.[53]	ZDB-ALT-011017-8; see https://zfin.org/
Zebrafish: <i>Tg(fli1:nEGFP)^{y7}</i>	Roman et al.[100]	ZDB-ALT-060821-4; see https://zfin.org/
Zebrafish: <i>Tg(fliiep:2xHA-plxnd1)</i>	This paper; see Carretero-Ortega et al.[77]	<i>Tg(fliiep:2xHA-plxnd1, myl7:EGFP)^{skt27}</i>
Zebrafish: <i>Tg(fliiep:klf2a)</i>	This paper	<i>Tg(fliiep:klf2a-P2A-mCherry-F, myl7:EGFP)^{skt28}</i>
Zebrafish: <i>Tg(fli1a:lifectGFP)^{mu240}</i>	Hamm et al.[192]	ZDB-ALT-170202-1; see https://zfin.org/
Zebrafish: <i>Tg(gata1a:dsRed)^{sd2}</i>	Traver et al.[187]	ZDB-ALT-051223-6; see https://zfin.org/
Zebrafish: <i>Tg(kdrl:mCherry)^{y206}</i>	Gore et al.[185]	ZDB-ALT-111104-1; see https://zfin.org/
Zebrafish: <i>Tg(kdrl:mRFP-F)^{y286}</i>	Yu et al.[117]	ZDB-ALT-151231-2; see https://zfin.org/
Zebrafish: <i>Tg(kdrl-NLS-mcherry)^{y173}</i>	Fujita et al.[90]	ZDB-ALT-110429-4; see https://zfin.org/
Zebrafish: <i>Tg(klf2a:H2b-EGFP)^{g11}</i>	Heckel et al.[87]	ZDB-ALT-161017-10; see https://zfin.org/
Zebrafish: <i>Tg(Kl(tjp1a-eGFP)^{pd1252}</i>	Levic et al.[112]	ZDB-ALT-231027-19; see https://zfin.org/
Morpholinos (zebrafish)		
MO2- <i>plxnd1</i> : 5'-CACACACTCACGTTGATGATGAG-3'	Gene Tools, LLC; see Torres-Vázquez et al.[59]	ZDB-MRPHLNO-100521-6; see https://zfin.org/
Vectors (zebrafish)		
p3E-B-globin intron-SV40 polyA	This paper	J.T-V. lab vector #3053
p3E-polyA	Kwan et al.[188]	Tol2 kit vector #302 (J.T-V. lab vector #548); see: http://tol2kit.genetics.utah.edu/index.php/List_of_entry_and_destination_vectors
p5E-fliiep	addgene; see Villefranc et al.[189]	addgene plasmid #31160; http://n2t.net/addgene:31160 ; RRID:Addgene_31160. (JTV lab vector #1044)
pCR8/GW/TOPO-TA-2xHA-zPlxnD1-WT	This paper	JTV lab vector #2027
pCR8/GW/TOPO-TA-Klf2a-P2A-mCherry-F	This paper	JTV lab vector #3089
pCS2FA-transposase	Kwan et al.[188]	Tol2 kit vector #396; see: http://tol2kit.genetics.utah.edu/index.php/List_of_entry_and_destination_vectors (JTV lab vector #557)
pDestTol2CG2	Kwan et al.[188]	Tol2 kit vector #395; see: http://tol2kit.genetics.utah.edu/index.php/List_of_entry_and_destination_vectors (JTV lab vector #1934)
pfliiep:2xHA-plxnd1, myl7:EGFP	This paper	JTV lab vector #3059
pfliiep:klf2a-P2A-mCherry-F, myl7:EGFP	This paper	JTV lab vector #3097
pME-klf2a	Renz et al.[94]	JTV lab vector #3036
pST1374-NLS-flag-linker-Cas9	addgene Shen et al.[190]	RRID:Addgene_44758 addgene plasmid # 44758; http://n2t.net/addgene:44758 ; (JTV lab vector #1253)
pUC19-T7-plxnd1-gRNA-01	This paper; see Table S1	JTV lab vector #1204
pUC19-T7-plxnd1-gRNA-02	This paper; see Table S1	JTV lab vector #1281
pUC19-T7-plxnd1-gRNA-03	This paper; see Table S1	JTV lab vector #1280
Generative AI and AI-assisted technologies used in the writing process		
ChatGPT	OpenAI	RRID:SCR_023775
Grammarly	Grammarly, Inc	RRID:SCR_023778
Software and algorithms		
AutoTube	Montoya-Zegarra et al.[193]	

CHOPCHOP	https://chopchop.cbu.uib.no/Montague et al. [194]	RRID:SCR_015723
CRISPRscan	https://www.crisprscan.org/Moreno-Mateos et al. [195]	RRID:SCR_023777
Fiji (versions 1.52n, 1.54f, and 2.9.0/1.54d)	http://fiji.sc Schindelin et al.[196]	RRID:SCR_002285
GraphPad Prism (versions 9.3, 9.3.1, and 10.1)	https://www.graphpad.com/See Lord et al. [186]	RRID:SCR_002798
ImageJ (version 1.53k)	Schneider et al.[197]	RRID:SCR_003070
MATLAB (R2021a release)	The MathWorks Inc. [198] https://www.mathworks.com/products/matlab.html	RRID:SCR_001622
Microsoft Excel	Microsoft Corporation	Microsoft Excel for Mac version 16.67.1 (22111300)
Microsoft PowerPoint	Microsoft Corporation	Microsoft PowerPoint for Mac version 16.69.1 (23011600)
Microsoft Word	Microsoft Corporation	Microsoft Word for Mac version 16.67 (22111300)
MicroZebraLab	Viewpoint Life Sciences https://www.viewpoint.fr/product/zebrafish/cardiology/microzebralab Benslimane et al.[51]	RRID:SCR_023750 Catalog #MZL
Poly Peak Parser	http://yosttools.genetics.utah.edu/PolyPeakParser/ Hill et al.[199]	RRID:SCR_023776
SnapGene (version 7.0.2 and older)	Dotmatics	RRID:SCR_015052
TIDE (Tracking of Indels by Decomposition)	https://tide.nki.nl/ Brinkman et al.[200]	RRID:SCR_023704
Vessel Analyzer	This paper	
Databases		
Daniocell	Sur et al.[92]	https://daniocell.nichd.nih.gov/
The Zebrafish Information Network (ZFIN)	Bradford et al.[201]	https://zfin.org/

EXPERIMENTAL MODELS AND SUBJECT DETAILS

Animals

Fish: We raised zebrafish (*Danio rerio*) in recirculating water systems (28°C, 14-hour light/10-hour dark cycle) at the NYU Grossman School of Medicine, following IACUC-approved animal protocols and under Veterinarian supervision (AAALAC International accredited). We bred fish in mating tanks, raising embryos to 5 dpf in Blue Water (comprising 20 L distilled water, 20 ml Methylene Blue aqueous solution (1g/L), and 6 grams of Instant Ocean sea salt for aquariums) or zebrafish system water (ZSW, the water in the aquaria) in a 28.5°C incubator. To prevent embryo pigmentation, we administered 1-Phenyl-2-thiourea (PTU) treatment before 24 hpf[202]. No tests were conducted on the influence of sex since sex determination occurs at later stages. **Mutant alleles:** *gata1a*^{m651} (putative null) contains a C-to-T transversion at position 1015 of the open reading frame, yielding a predicted nonsense mutation at Arg339, truncating the last 79 aa of the Gata1a protein, including part of the basic domain critical for DNA binding[108]. *klf2a*^{y616} (putative null) contains an eight bp insertion in exon 2, resulting in a frameshift and early termination, encoding an 181 aa protein with the N-terminal 157 residues of the 380 aa WT product[86] (transactivation domain and trans-repression domain fragment; see[93]). *klf2b*^{sa43252} (putative null)[97] harbors a C-to-A transversion at position 32 of exon 1, converting Ser11 into a stop codon and truncating 353 aa. *plxnd1*^{Df(Chr08)fs311} (null) is a chromosomal deficiency of *plxnd1* and nearby genes[58, 59]. *plxnd1*^{fov01b} (null) harbors a C-to-A transversion converting Tyr318 to a stop codon, truncating the 1,880 aa receptor early in its N-terminal extracellular Sema domain. Reduced mutant message expression is likely due to nonsense mRNA decay[58-60]. *plxnd1*^{GAP1} (*plxnd1*^{skt25}) and *plxnd1*^{GAP2} (*plxnd1*^{skt26}) delete and replace two amino acids in the receptor's GAP1 and GAP2 motifs[26, 62-64] (this study, **Table S1**), likely eliminating the receptor's GAP function. *sih*^{tc300b} (null) features an A-to-G transition at the -2 position of the splice-acceptor in the second intron of *tnt2a*, causing a frameshift and a premature stop codon in exon 7. The mutant message encodes only the first 11 aa of the WT protein[54]. **Transgenic lines:** *TgBAC(tjp1a-eGFP)*^{pd1252}[112], *Tg(fli:nEGFP)*^{y7}[100], *Tg(fli1:EGFP)*^{y1}[53], *Tg(fli1a:lifeactGFP)*^{mu240}[192], *Tg(fliep:2xHA-plxnd1)* and *Tg(fliep:klf2a)* (this study), *Tg(kdrl:mCherry)*^{y206}[185], *Tg(kdrl:mRFP-F)*^{y286}[117], *Tg(kdrl:nls-mCherry)*^{y173}[90], and *Tg(klf2a:H2b-EGFP)*^{g11}[87]. Consult the **KEY RESOURCE TABLE**.

Mice: We used the *Tie2*^{Cre} endothelial-specific Cre line[127] and the floxed *Plxnd1* allele *Plxnd1*^{flox}[71, 74]. See the **KEY RESOURCE TABLE**.

Engineered microvascular networks (MVNs) made from human ECs and application of flow

We fabricated microfluidic chips[203, 204] and pumps[205] from Polydimethylsiloxane (PDMS, Dow Corning Sylgard 184, Ellsworth Adhesives), assembling them as described before. We formed MVNs by suspending 7 million/ml HUVECs (Human Umbilical Vein Endothelial Cells; isolated and cultured as in[206] and carrying a flow-inducible reporter of *KLF2* transcription[123] and 1 million/ml of human lung fibroblasts (Lonza) in 1.4 U/mL of thrombin (Sigma-Aldrich) and 3 mg/mL of fibrinogen (Sigma-Aldrich) and injecting the cell suspension into the microfluidic chips. We maintained the resulting devices in Vasculife VEGF medium but with only a quarter (0.19 U/mL) of the heparin sulfate provided in the kit (Lifeline Cell Technology), changing the medium daily. We applied constant flow, resulting in a mean shear stress of 0.5 Pa in the MVNs using the microfluidic pump starting on day 5 of the culture. We maintained the flow for 48 hours before evaluating the MVNs. We did not expose MVNs cultured under static conditions to flow. We provide further details about these protocols in[124]. See also [125, 126]. Consult the **KEY RESOURCE TABLE**.

METHOD DETAILS

Animal genotyping

We amplified PCR products from DNA isolated from zebrafish (adult fin clips or whole embryos or larvae) and murine (embryo yolk sacs and adult tail biopsies) lysates, using BioReady Taq DNA polymerase for the former. We analyzed the PCR products by agarose gel electrophoresis, Sanger sequencing, or both. We handled and annotated zebrafish allele sequences using SnapGene software.

Zebrafish: genome editing

We generated *plxnd1*^{GAP} alleles using CRISPR/Cas9-based genome editing[61], as in[77]. We selected gRNA targets using CHOPCHOP[194] and CRISPRscan[195] web tools. We used T7 RNA polymerase or the MEGashortscript T7 kit to *in vitro* transcribe gRNAs from the pUC19-T7-plxnd1-gRNA-01, pUC19-T7-plxnd1-gRNA-02, and pUC19-T7-plxnd1-gRNA-03 vectors (made via PCR-assembly of oligo templates (Integrated DNA Technologies)[62, 207] subcloned into pUC19-T7[207]). We induced editing by delivering 1 nl of a mix of gRNA

(125 pg) and *S. pyogenes* Cas9 nuclease mRNA (300 pg; transcribed from pST1374-NLS-flag-linker-Cas9[190]) or protein (500 pg; PNA Bio) into one-cell stage *Tg(fli1a:EGFP)^{y1}*[53] G0 embryos. We pooled genomic DNA from 4–12 G0s to assess genome editing, generating PCR amplicons with BioReady Taq DNA polymerase. We analyzed PCR products by agarose gel electrophoresis or sequencing (after TOPO-TA cloning into pCRII-TOPO or pCR2.1-TOPO vectors, with 8-20 colonies evaluated). We identified adult G0s with germline mutations via individual outcrossing with *plxnd1^{fov01b}*; *Tg(fli1a:EGFP)^{y1}* mutants, scoring the progeny for vascular misguidance. We outcrossed carrier G0s to WT *Tg(fli1a:EGFP)^{y1}* fish to create F1 fish. We identified F1 heterozygous carriers via PCR genotyping and analysis of the sequence trace using the Poly Peak Parser[199] and TIDE[200] web tools. We confirmed allele sequences by single-colony Sanger sequencing of TOPO-TA cloned PCR products amplified from F1 genomic DNA. See **Table S1** and the **KEY RESOURCE TABLE**.

Zebrafish: constructs for making transgenic lines

To make the *Tg(fliiep:2xHA-plxnd1)* (full name: *Tg(fliiep:2xHA-plxnd1, myl7:EGFP)^{skt27}*) and *Tg(fliiep:klf2a)* (full name: *Tg(fliiep:klf2a-P2A-mCherry-F, myl7:EGFP)^{skt28}* lines, we assembled the J.T-V. lab vectors #3059 (pfliiep:2xHA-plxnd1, myl7:EGFP)[77] and #3097 (pfliiep:klf2a-P2A-mCherry-F, myl7:EGFP) via Gateway cloning[208] using the Gateway LR Clonase Enzyme mix. We recombined the pDestTol2CG2 destination vector (with myl7:EGFP cardiac marker)[188], the entry clone p5E-fliEP (for endothelial expression)[189], and these other entry clones. For #3059: J.T-V. lab vectors #2027 (pCR8/GW/TOPO-TA-2xHA-zPlxnD1-WT; a pCR8/GW/TOPO TA derivative) and #3053 (p3E-B-globin intron-SV40 polyA). The latter includes the rabbit β -globin intron and the SV40 late polyA signal to promote mRNA export and enhance protein expression[209-213], enabling efficient expression of ~6 kb cDNAs. For #3097, J.T-V. lab vectors #3089 (pCR8/GW/TOPO-TA-Klf2a-P2A-mCherry-F-P2A-mCherry-F and p3E-polyA)[188]. Vector #3089 is a derivative of pCR8/GW/TOPO TA and pME-klf2a[94] made for P2A-based equimolar co-expression[214] of piscine Klf2a and farnesylated mCherry. J.T-V. lab vectors #2027 and #3089 harbor the optimal 5' zebrafish KOZAK sequence (5'-GCAAAC-3')[215] upstream of the 2xHA-zPlxnD1-WT (5,709 bp) and Klf2a (1,140 bp) ORFs to enhance expression. We designed and annotated plasmids using SnapGene software. We amplified PCR products for plasmid construction with Phusion High-Fidelity or BioReady Taq DNA polymerases. We made our entry clones via Gibson assembly[216]. See the **KEY RESOURCE TABLE**.

Zebrafish: transgenesis

We performed Tol2-based transgenesis[217] with the J.T-V. lab vectors #3059 (pfliiep:2xHA-plxnd1, myl7:EGFP) and #3097 (pfliiep:klf2a-P2A-mCherry-F, myl7:EGFP) to make the *Tg(fliiep:2xHA-plxnd1)* (full name: *Tg(fliiep:2xHA-plxnd1, myl7:EGFP)^{skt27}*) and *Tg(fliiep:klf2a)* (full name: *Tg(fliiep:klf2a-P2A-mCherry-F, myl7:EGFP)^{skt28}* lines. We injected one nl of a solution containing 100 pg of Tol2 mRNA (synthesized *in vitro* from the pCS2FA-transposase vector[188]) and 200 pg of the transgenesis vector into the cytoplasm of one-cell stage *plxnd1^{fov01b}* mutants carrying the *Tg(kdrl:mCherry)^{y206}*, *Tg(fli:nEGFP)^{y7}*, or *Tg(fli1a:lifeactGFP)^{mu240}* endothelial reporters[100, 185, 192]. We scored G0 embryos at 1-3 dpf, raising the animals with cardiac green fluorescence. To make F1 lines, we outcrossed the G0s with *plxnd1^{fov01b}* mutants, selecting fish with green hearts. We established F2 lines from single F1 fish. Expression of the farnesylated mCherry from the *Tg(fliiep:klf2a)* line is usually undetectable by confocal microscopy in 1-3 dpf fish. See the **KEY RESOURCE TABLE**.

Zebrafish: immunofluorescence

Embryos were fixed overnight (ON) at 4°C in 4% paraformaldehyde (PFA) solution in phosphate-buffered saline (PBS), pH 7.5. The embryos were then washed six times (10 min/wash) with PBST (PBS with 0.2% Tween) and incubated in the blocking solution (PBST with 1% bovine serum albumin (BSA)) for 1 hr, all at room temperature (RT). Embryos were then incubated ON at 4°C with primary antibodies diluted in blocking solution and then washed with PBST six times (10 min/wash) at RT. The embryos were then incubated overnight at 4°C with fluorescent secondary antibodies diluted in the blocking solution (2 hr at RT or ON at 4°C). Next, embryos were washed four times in PBST (15 min/wash) at RT and mounted before confocal imaging. Antibody pairs and dilutions: chicken anti-GFP (1:1000) and Alexa Fluor 488 goat anti-chicken (1:1000); rat anti-HA (1:500) and Alexa Fluor 647 donkey anti-rat (1:1000); sheep anti-mCherry[191] (1:1000) and Cy3 donkey anti-sheep (1:1000). See the **KEY RESOURCE TABLE**.

Zebrafish: morpholino injections

We diluted the splice-blocking MO2-*plxnd1* morpholino[59] (GeneTools, LLC) in water with phenol red. We delivered 2.5 ng of the morpholino into the cytoplasm of one-cell stage zebrafish embryos via microinjection of 2-4 nl of the morpholino solution (as in[59]). Consult the **KEY RESOURCE TABLE**.

Zebrafish: embryo mounting for confocal imaging

We mounted live and fixed, immunofluorescently stained zebrafish embryos on their side by embedding them within a cooling globule of a 0.5% low-melt AquaPor HR GTAC Agarose (national diagnostics) solution in distilled water. Before mounting live embryos, we anesthetized them in zebrafish system water (ZSW) with 0.4 mg/mL of Tricaine (ZSW-0.4T). To collect images for analyses of EC morphometry with the *Vessel Analyzer* app, we mounted the embryos on a Fisherbrand Frosted Microscope Slide, topping the globule with a square cover glass. For other applications, we mounted the fish in an agarose globule on a 35 mm plastic Petri dish (Falcon). Refer to the **KEY RESOURCE TABLE**.

Zebrafish: confocal microscopy

We took lateral images of the trunk of live and fixed, immunofluorescently stained embryos of the region found dorsal to the yolk extension. We employed a Leica TCS SP8 confocal microscope, the 488, 561, and 647 nm laser lines, and these Leica objectives: 40x /1.10 N.A. HC PL APO W CORR CS2 water immersion (for image analyses using the *Vessel Analyzer* app) and 40x/0.8 N.A. HCX APO L U-V-I water dipping (for everything else). In the images used for quantification, the total depth span of the Z-stack is larger than the axial vessels' width. The sections below provide further imaging details.

Zebrafish: imaging and quantification of the DA caliber

We used confocal imaging (pin-hole size: 1; digital zoom: 0.75; z-step size: 1.2 μ m; speed: 600 Hz; line averaging: 2x; 16-bit image resolution; format (image size in pixels): 1024x512 (24, 48 hpf) and 1024x704 (72 hpf); 488 or 561 nm laser lines) of live or fixed, immunostained embryos to visualize the vasculature with the *Tg(fli1:EGFP)^{y7}*[53] or (*kdr1:mCherry*)²⁰⁶[185] endothelial cytosolically-targeted fluorescent reporters within a region spanning four (at 24 hpf) or three somites (after 24 hpf). We made orthogonal projections from each Z-stack at roughly the midpoint of each somite to create three or four virtual DA cross-sections. We manually traced the DA's luminal perimeter in each orthogonal projection and then measured the enclosed area. The average of these measurements is the DA caliber reported for each embryo. We processed the images, traced the DA's luminal perimeter, and automatically extracted the DA's caliber using FIJI software (versions 1.52n and 1.54f)[196]. We note that we measured the DA caliber using live or fixed embryos. Importantly, our comparisons involve fish under the same conditions as the figure legends note. While we did not determine the impact of fixation on DA caliber at 24 and 32 hpf, we tested its effects at 48 and 72 hpf. We found no significant difference in DA caliber at 48 hpf between live and fixed embryos. However, at 72 hpf, the DA caliber of fixed embryos appears smaller than that of live fish. Look at the **KEY RESOURCE TABLE**.

Zebrafish: imaging and quantification of the DA's EC abundance

We utilized confocal imaging (pin-hole size: 1; digital zooms: 1 (24 hpf), 0.75 (32, 48, and 84 hpf); z-step size: 1.2 μ m; speed: 600 Hz; line averaging: 2x; 16-bit image resolution; format (image size in pixels): 1024x512 (24, 48 hpf), 1024x704 (72 hpf), 1024x768 (84 hpf); 488 nm laser line), of live embryos to visualize the *Tg(fli:nEGFP)^{y7}* pan-endothelial nuclear reporter[100] within a DA segment (145.45 μ m at 24 hpf, 193.94 μ m at 32 hpf, 218.18 μ m at 48 hpf, and 266.67 μ m at 72 and 84 hpf), employing the maximum intensity projection from each Z-stack to quantify the number of ECs manually. Guided by the regular positioning of the Se vessels (see[58, 72, 218]), we calculated the average somite length for each stage and genotype (except for *plxnd1* mutants, for which we used the WT-like sibs' values). Average somite lengths: 29-32 μ m (24 hpf), 32-36.6 μ m (32 hpf), 42-48 μ m (48 hpf), 61.4-66.7 μ m (72 hpf) and 68-70 μ m (84 hpf). Using the appropriate age-specific value, we converted the span of the imaged DA's segment into somite lengths. To calculate the ratio of DA's ECs/somite, we divided the DA's EC counts by the number of somite lengths. We processed the images using FIJI software (versions 1.52n and 1.54f)[196]. Consult the **KEY RESOURCE TABLE**.

Zebrafish: imaging and quantification of the DA's endothelial *Tg(klf2a:H2b-EGFP)^{ig11}* levels

We employed confocal imaging (pin-hole size: 1; digital zoom: 0.75; z-step size: 1.2 μ m; speed: 600 Hz; line averaging: 2x; 16-bit image resolution; format (image size in pixels): 1024 x704; using the 488 nm and 561 nm laser lines sequentially) of live embryos to co-visualize the signals from the *Tg(klf2a:H2b-EGFP)^{ig11}* transcriptional *klf2a* nuclear reporter (expressed in the endothelium and other tissues[87]) and the *Tg(kdr1:nls-*

mCherry^{y173} blood endothelium nuclear marker[90]. We used the latter to create a binary mask, automatically defining regions of interest specific to the endothelial signals of the former. Subsequently, we aggregated the intensities of the H2b-EGFP signals across the Z-stack and represented them using a color scale. To prepare the graphs, we first calculated the mean fluorescent intensity for each EC. Then, we averaged the mean intensities of the ECs within the DA for each embryo. We processed the images and extracted fluorescent intensities using FIJI software(versions 1.52n and 1.54f)[196]. Check the **KEY RESOURCE TABLE**.

Zebrafish: imaging and quantification of EC morphometry with the Vessel Analyzer app

We used confocal imaging (pin-hole size: 1; digital zoom: 1; z-step size: 0.42 μm ; speed: 600 Hz; line averaging: 2x; 16-bit image resolution; format (image size in pixels): 1024x348; voxel size: 0.2841 x 0.2841 x 0.4249 mm^3 ; employing the 488 nm and 561 nm laser lines sequentially) to image in live embryos the tight junction ZO-1 fluorescent protein fusion from the *TgBAC(tjp1a-eGFP)*^{pd1252} knock-in line[112] and the *Tg(kdr1:mRFP-F)*^{y286} blood endothelium's cell membrane label[117]. The captured dual-channel image files were processed using our in-house developed *Vessel Analyzer* app programmed on MATLAB (R2021a release; MathWorks®)[198].

This tool offers a detailed EC and vessel morphology analysis, allowing for comparisons across stages and genotypes. The app automatically defines the outer and luminal perimeters and the lumen center in planes orthogonal to the vessel's axis ("cross-sections") for the user-selected vessel segment (in this case, a DA portion). It then projects the EC junctions in the vessel wall from the lumen center into a cylinder. Next, the software unwraps the cylinder surface into a plane from the 0-degree line. The unwrapped 2D surface facilitates the identification of individual ECs' perimeters. The software presents two adjacent plane copies to facilitate the segmentation of EC junctions that cross the 0-degree generating line. The user then manually traces a polygon following the junctional signals to provide a skeleton of the cell perimeter. An algorithm then identifies all junction points close to the polygon to refine the cell's borders. The refined perimeter of each cell is back-projected in its original position into a 3D vessel model to create a 3D model of the cell. A 3D rendering allows visualization of the vessel's luminal and outer surfaces, along with EC junctions projected into either surface. Alternatively, the model displays the vessel's luminal surface and the volume of any selected EC. The 3D models of the vessel and its constituent ECs enable their morphometric quantification. At the cellular level, the app's outputs include the following single-EC morphometry parameters measured at the vessel's luminal surface. (1) **Perimeter**. (2) **Length** (axial length connecting the two perimeter points furthest apart along the vessel's axis). (3) **Width** (the transversal length connecting the two most distant perimeter points). (4) **Area** (integration of the total surface occupied by the cell). (5) **elongation** (the length/width ratio). The software also calculates the (6) **cell's volume** by integrating the cell's height between the luminal and basal areas. Additionally, the app uses each EC's mass distribution (assuming uniform density) to calculate the moment of the inertia tensor around the cell's center of mass. This mass distribution-dependent parameter measures the cell's resistance to rotation. With this parameter, the app calculates three more measures for each cell. The (7) **mean moment of inertia** (the average moment along all directions). The (8) **anisotropy of the inertia moment** (which measures how much the cell's moment of inertia values differ along its principal axes). The (9) **alignment angle** or **angle with the vessel's axis** (θ), the arc between the cell's minor principal axis of rotation (associated with cell length), and the vessel's longitudinal axis. The software additionally quantifies the vessel's 3D model. For each cross-section, the app provides five vascular morphometry outputs. These are as follows. The (1) **outer** and (2) **luminal perimeters** that circumscribe the endothelial basal and apical surfaces, respectively. The (3) **maximum** and (4) **minimum luminal diameters**. The (5) **caliber** (the luminal area enclosed by the luminal perimeter). Finally, the software provides two measures of variation of vessel morphometry: (1) **variability in vessel caliber** (the standard deviation of the latter) and (2) **vessel's tortuosity** (a measure of how much the vessel deviates from being a straight tube), namely the ratio of the distance connecting lumen centers across cross-sections along the vessel segment over the straight-line distance between its endpoints). The *Vessel Analyzer* app automatically saves all morphometric outputs into two Microsoft Excel tables corresponding to EC and vessel data. We used GraphPad Prism (versions 9.3 and 10.1) software for statistical analysis of this data and graph generation. **See the KEY RESOURCE TABLE.**

Zebrafish: Quantification of heartbeat frequency with the MicroZebraLab system

We anesthetized the embryos in ZSW-0.4T for 5 minutes and fast-washed them in ZSW to rinse away the anesthetic solution. We mounted the embryos on their side by embedding them within a cooling globule of 0.5% low-melt AquaPor HR GTAC Agarose (national diagnostics) solution in distilled water in the center of a 35 mm plastic Petri dish (Falcon). Before imaging, we added ZSW into the Petri dish and placed it in a 28.5°C incubator for 1 hour to enable heartbeat normalization. We used the MicroZebraLab system (Viewpoint Life Sciences) to

perform semi-automated measurements of the heartbeat frequency. This software relies on pixel density changes within the region of interest under transmitted light to calculate cardiovascular parameters; see[51]. We collected 1-minute avi format videos of the heart (both ventricle and atrium) with a frame rate of 30 frames per second and a resolution of 640 x 512 pixels using a trinocular compound microscope (SWIFT SW380T, Swift Optical Instruments Inc) equipped with a Siedentopf head, a mechanical stage, an Abbe condenser, and an LED lamp. The videos were collected using the microscope's 10x DIN (Deutsche Industrie Norm: 160 mm focal tube length) achromatic objective (0.25 NA and 6.54 mm working distance) and a Teledyne FLIR GS3-U3-41C6 camera (FLIR Integrated Imaging Solutions, Inc) mounted on the microscope's third eyepiece. The software ran on a Dell Optiplex 3000 SFF computer with a 256 GB SSD drive for data storage. Consult the **KEY RESOURCE TABLE**.

Mouse: generation of endothelial *Plxnd1* knockout (*Plxnd1*^{ECKO}) animals

We crossed *Tie2*^{Cre/+} mice[127] with *Plxnd1*^{flox/flox} mice[71] and then back-crossed the *Tie2*^{Cre/+};*Plxnd1*^{flox/+} offspring with *Plxnd1*^{flox/flox} mice to produce control (*Plxnd1*^{flox/flox}, *Plxnd1*^{flox/+} or *Tie2*^{Cre/+};*Plxnd1*^{flox/+}) and endothelial *Plxnd1* knockout (*Tie2*^{Cre/+};*Plxnd1*^{flox/flox}) embryos. See the **KEY RESOURCE TABLE**.

Mouse: histology and immunohistochemistry

We harvested embryos at embryonic day 11.5 (E11.5) from timed pregnancies, considering the afternoon of the plug date as E0.5. Subsequently, we fixed the embryos in 4% PFA, dehydrated them in ethanol, and processed them for paraffin embedding and transverse sectioning. Following dewaxing, we prepped the sections for immunostaining by performing antigen retrieval, rehydration, and blocking in 5% BSA-PBST (0.1%) for 2-3 hours at room temperature. We then incubated the sections with primary antibodies overnight at 4°C, followed by washing and incubation in diluted secondary antibodies for 1-2 hrs at room temperature. To visualize the nuclei, we used DAPI counterstain (see[74, 128]). The antibody pairs and their respective dilutions were as follows. Monoclonal rabbit anti-ERG1 (1:100) and Alexa Flour goat anti-rabbit 647 (1:350). Monoclonal rat anti-Pecam1 (1:50) and Alexa Flour goat anti-rat 488 (1:350). We performed standard H&E staining for gross histological analysis as described in[128-130]. Check the **KEY RESOURCE TABLE**.

Mouse: measurement of the DA's luminal cross-sectional area and perimeter and statistical analyses

We scored 4 to 5 embryos in each group (control and *Plxnd1*^{ECKO}). We used images of 3 sections per embryo from the cardiac level to calculate the luminal area and perimeter of both the right and the left DA. We quantified all images with ImageJ 1.53k software[197]. We conducted statistical analyses using the two-tailed Student's *t*-test. We present the data as mean ± standard error of the mean (SEM). Significant differences, *p* < 0.05. We used GraphPad Prism version 9.3.1 (GraphPad Software, USA) for statistical analyses. See the **KEY RESOURCE TABLE**.

MVNs: fixation and immunofluorescent staining

We fixed the engineered MVNs in 4% paraformaldehyde solution (Thermo Fisher Scientific) for 15 minutes, rinsing them thrice with Phosphate-Buffered Saline (PBS, Thermo Fisher Scientific) for 5 minutes each time. We applied these solutions through the media channels of the microfluidic devices, placing the devices on a rocker during fixation and staining. We simultaneously blocked and permeabilized using a solution of 10% goat serum (Gibco) and 1% Triton X-100 (Fisher Scientific) in PBS for 3 hours at room temperature. For immunofluorescence, we applied a 1:50 dilution of a primary mouse antibody against human CD144/VE-cadherin (BD Pharminogen) in 1% goat serum (Gibco) and 0.2% Triton X-100 in PBS overnight at 4°C. We rinsed the samples for 6 hours using frequent changes of PBS solution. We incubated the samples in a 1:200 dilution of goat anti-mouse IgG1 AlexFluor 647 (Thermo Fisher Scientific) and 300 nM DAPI (Thermo Fisher Scientific) overnight at 4°C. We subsequently rinsed the MVNs by frequent exchanges in PBS for several hours, leaving the MVNs in PBS overnight at 4°C before imaging. Check the **KEY RESOURCE TABLE**.

MVNs: confocal microscopy for vessel caliber measurements

We added fluorescent dextran (Texas Red, 70,000 MW) to the media channels of microfluidic devices perfused through the MVNs. We acquired confocal images using an LSM 710 confocal microscope (Zeiss) at a resolution of 2.4 pixels/μm and a z-spacing of 5 μm (10x dry objective). We generated maximum intensity projection (MIP) images and performed background subtraction using Fiji software (version 2.9.0/1.54d)[196]. We used AutoTube software[193] to calculate the vascular caliber. We performed MIP image pre-processing via adaptive histogram equalization, illumination correction, and image denoising through Block-Matching and 3D Filtering. We executed

tube detection with the Multi-Otsu thresholding. We removed short ramifications (length smaller than 20 pixels) and merged branch points within a 22-pixel radius. Check the **KEY RESOURCE TABLE**.

MVNs: confocal microscopy for KLF2-GFP expression quantification

We acquired confocal images using an LSM 710 confocal microscope (Zeiss) at a resolution of 1.2 pixels/ μm and a z-spacing of 2 μm (20x dry objective). We generated maximum intensity projection (MIP) images using Fiji software (version 2.9.0/1.54d)[196]. We used Matlab (Version R2022b, The MathWorks, Inc.) to calculate a global threshold level for each image, binarize the image by applying the threshold to identify the GFP-positive pixels, and calculate the percentage of the image that is positive for GFP. Consult the **KEY RESOURCE TABLE**.

MVNs: confocal microscopy for EC area measurements

Following immunostaining, we performed tiling imaging of the MVNs using an LSM 710 confocal microscope (Zeiss) at a resolution of 2.4 pixels/ μm and a z-spacing of 1 μm (40x dry objective). We used the maximum intensity projection (MIP) images to calculate cell area using Fiji software (version 2.9.0/1.54d)[196]. We pre-processed the z-stacks by applying Background Subtraction and Median Filtering before creating MIPs. We further processed the MIPs by applying a Gaussian filter. Then, we segmented the cells using the “Morphological Segmentation” plugin[219] of Fiji before computing the area of each segmented cell. We compared these automated measurements against measurements from manual segmentation of cell borders, confirming that the automatic method provides accurate area computations. See the **KEY RESOURCE TABLE**.

QUANTIFICATION AND STATISTICAL ANALYSES

Zebrafish: See the legends of **Figures 1-4, S3-S5, and S7**. **Mouse:** See **Figure 6** and the “Quantification of the murine DA’s luminal cross-sectional area and perimeter and statistical analyses” section. **MVNs:** See the legend of **Figure 5**.

SUPPLEMENTAL INFORMATION

Zebrafish lines generated in this study

Mutant alleles: *plxnd1*^{GAP1} (*plxnd1*^{skt25}) and *plxnd1*^{GAP2} (*plxnd1*^{skt26}); see **Table S1, Zebrafish genome editing**, and the **KEY RESOURCE TABLE**. Transgenic lines: *Tg(fliiep:2xHA-plxnd1)* (full name: *Tg(fliiep:2xHA-plxnd1, myl7:EGFP)*^{skt27}) and *Tg(fliiep:klf2a)* (full name: *Tg(fliiep:klf2a-P2A-mCherry-F, myl7:EGFP)*^{skt28}). See **Zebrafish constructs for making transgenic lines, Zebrafish transgenesis**, and the **KEY RESOURCE TABLE**.

Cell lines generated in this study

None.

REFERENCES

1. Vignes, H., C. Vagena-Pantoula, and J. Vermot, *Mechanical control of tissue shape: Cell-extrinsic and -intrinsic mechanisms join forces to regulate morphogenesis*. *Semin Cell Dev Biol*, 2022. **130**: p. 45-55.
2. Duchemin, A.L., et al., *Mechanotransduction in cardiovascular morphogenesis and tissue engineering*. *Curr Opin Genet Dev*, 2019. **57**: p. 106-116.
3. Daems, M., H.M. Peacock, and E.A.V. Jones, *Fluid flow as a driver of embryonic morphogenesis*. *Development*, 2020. **147**(15).
4. Agarwal, P. and R. Zaidel-Bar, *Mechanosensing in embryogenesis*. *Curr Opin Cell Biol*, 2021. **68**: p. 1-9.
5. Red-Horse, K. and A.F. Siekmann, *Veins and Arteries Build Hierarchical Branching Patterns Differently: Bottom-Up versus Top-Down*. *Bioessays*, 2019. **41**(3): p. e1800198.
6. Klabunde, R., *Cardiovascular Physiology Concepts Web Site*. 1999-present.
7. Jacob, M., D. Chappell, and B.F. Becker, *Regulation of blood flow and volume exchange across the microcirculation*. *Crit Care*, 2016. **20**(1): p. 319.
8. Santamaria, R., et al., *Remodeling of the Microvasculature: May the Blood Flow Be With You*. *Front Physiol*, 2020. **11**: p. 586852.
9. Wen, L., et al., *The role of blood flow in vessel remodeling and its regulatory mechanism during developmental angiogenesis*. *Cell Mol Life Sci*, 2023. **80**(6): p. 162.
10. Barrasa-Ramos, S., et al., *Mechanical regulation of the early stages of angiogenesis*. *J R Soc Interface*, 2022. **19**(197): p. 20220360.
11. Urner, S., et al., *Mechanotransduction in Blood and Lymphatic Vascular Development and Disease*. *Adv Pharmacol*, 2018. **81**: p. 155-208.
12. Yamashiro, Y. and H. Yanagisawa, *The molecular mechanism of mechanotransduction in vascular homeostasis and disease*. *Clin Sci (Lond)*, 2020. **134**(17): p. 2399-2418.
13. Lee, R.M., J.G. Dickhout, and S.L. Sandow, *Vascular structural and functional changes: their association with causality in hypertension: models, remodeling and relevance*. *Hypertens Res*, 2017. **40**(4): p. 311-323.
14. Ma, J., et al., *Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions*. *Signal Transduct Target Ther*, 2023. **8**(1): p. 168.
15. Zuela-Sopilniak, N. and J. Lammerding, *Can't handle the stress? Mechanobiology and disease*. *Trends Mol Med*, 2022. **28**(9): p. 710-725.
16. Andres-Delgado, L. and N. Mercader, *Interplay between cardiac function and heart development*. *Biochim Biophys Acta*, 2016. **1863**(7 Pt B): p. 1707-16.
17. Trinidad, F., et al., *Effect of Blood Flow on Cardiac Morphogenesis and Formation of Congenital Heart Defects*. *J Cardiovasc Dev Dis*, 2022. **9**(9).
18. Libby, P., et al., *Atherosclerosis*. *Nat Rev Dis Primers*, 2019. **5**(1): p. 56.
19. Tamargo, I.A., et al., *Flow-induced reprogramming of endothelial cells in atherosclerosis*. *Nat Rev Cardiol*, 2023. **20**(11): p. 738-753.
20. Wang, X., et al., *Endothelial mechanobiology in atherosclerosis*. *Cardiovasc Res*, 2023. **119**(8): p. 1656-1675.
21. Campinho, P., A. Vilfan, and J. Vermot, *Blood Flow Forces in Shaping the Vascular System: A Focus on Endothelial Cell Behavior*. *Front Physiol*, 2020. **11**: p. 552.
22. Roux, E., et al., *Fluid Shear Stress Sensing by the Endothelial Layer*. *Front Physiol*, 2020. **11**: p. 861.
23. Fang, Y., D. Wu, and K.G. Birukov, *Mechanosensing and Mechanoregulation of Endothelial Cell Functions*. *Compr Physiol*, 2019. **9**(2): p. 873-904.
24. Li, H., et al., *Endothelial Mechanosensors for Atheroprone and Atheroprotective Shear Stress Signals*. *J Inflamm Res*, 2022. **15**: p. 1771-1783.
25. Aitken, C., et al., *Mechanisms of endothelial flow sensing*. *Nature Cardiovascular Research*, 2023. **2**(6): p. 517-529.
26. Gay, C.M., T. Zygmunt, and J. Torres-Vazquez, *Diverse functions for the semaphorin receptor PlexinD1 in development and disease*. *Dev Biol*, 2011. **349**(1): p. 1-19.
27. Valdembri, D., et al., *Class 3 semaphorins in cardiovascular development*. *Cell Adh Migr*, 2016. **10**(6): p. 641-651.
28. Zhang, Y.F., et al., *Insights into the regulatory role of Plexin D1 signalling in cardiovascular development and diseases*. *J Cell Mol Med*, 2021. **25**(9): p. 4183-4194.

29. Mehta, V., et al., *The guidance receptor plexin D1 is a mechanosensor in endothelial cells*. Nature, 2020. **578**(7794): p. 290-295.
30. SenBanerjee, S., et al., *KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation*. J Exp Med, 2004. **199**(10): p. 1305-15.
31. Novodvorsky, P. and T.J. Chico, *The role of the transcription factor KLF2 in vascular development and disease*. Prog Mol Biol Transl Sci, 2014. **124**: p. 155-88.
32. Parmar, K.M., et al., *Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2*. J Clin Invest, 2006. **116**(1): p. 49-58.
33. Oates, A.C., et al., *The zebrafish klf gene family*. Blood, 2001. **98**(6): p. 1792-801.
34. Zhou, Z., et al., *Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling*. Nature, 2016. **532**(7597): p. 122-6.
35. Kwon, H.B., et al., *In vivo modulation of endothelial polarization by Apelin receptor signalling*. Nat Commun, 2016. **7**: p. 11805.
36. Choi, J.P., et al., *Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations*. Sci Adv, 2018. **4**(11): p. eaau0731.
37. Li, W., et al., *Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations*. Elife, 2021. **10**.
38. Kotlyarov, S. and A. Kotlyarova, *Participation of Kruppel-like Factors in Atherogenesis*. Metabolites, 2023. **13**(3).
39. Niu, N., et al., *Targeting Mechanosensitive Transcription Factors in Atherosclerosis*. Trends Pharmacol Sci, 2019. **40**(4): p. 253-266.
40. Xu, S., *Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis*. Pharmacol Res, 2020. **155**: p. 104737.
41. Tiezzi, M., H. Deng, and N. Baeyens, *Endothelial mechanosensing: A forgotten target to treat vascular remodeling in hypertension?* Biochem Pharmacol, 2022. **206**: p. 115290.
42. Dabravolski, S.A., et al., *The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy*. Biomedicines, 2022. **10**(2).
43. Gimbrone, M.A., Jr. and G. Garcia-Cardena, *Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis*. Circ Res, 2016. **118**(4): p. 620-36.
44. Bagatto, B. and W. Burggren, *A three-dimensional functional assessment of heart and vessel development in the larva of the zebrafish (Danio rerio)*. Physiol Biochem Zool, 2006. **79**(1): p. 194-201.
45. Malone, M.H., et al., *Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae*. BMC Biotechnol, 2007. **7**: p. 40.
46. Parker, T., et al., *A multi-endpoint in vivo larval zebrafish (Danio rerio) model for the assessment of integrated cardiovascular function*. J Pharmacol Toxicol Methods, 2014. **69**(1): p. 30-8.
47. De Luca, E., et al., *ZebraBeat: a flexible platform for the analysis of the cardiac rate in zebrafish embryos*. Scientific Reports, 2014. **4**.
48. Margiotta-Casaluci, L., et al., *Testing the Translational Power of the Zebrafish: An Interspecies Analysis of Responses to Cardiovascular Drugs*. Front Pharmacol, 2019. **10**: p. 893.
49. Gierten, J., et al., *Automated high-throughput heartbeat quantification in medaka and zebrafish embryos under physiological conditions*. Sci Rep, 2020. **10**(1): p. 2046.
50. Salman, H.E. and H.C. Yalcin, *Advanced blood flow assessment in Zebrafish via experimental digital particle image velocimetry and computational fluid dynamics modeling*. Micron, 2020. **130**: p. 102801.
51. Benslimane, F.M., et al., *Cardiac function and blood flow hemodynamics assessment of zebrafish (Danio rerio) using high-speed video microscopy*. Micron, 2020. **136**: p. 102876.
52. Sugden, W.W., et al., *Endoglin controls blood vessel diameter through endothelial cell shape changes in response to haemodynamic cues*. Nat Cell Biol, 2017. **19**(6): p. 653-665.
53. Lawson, N.D. and B.M. Weinstein, *In vivo imaging of embryonic vascular development using transgenic zebrafish*. Dev Biol, 2002. **248**(2): p. 307-18.
54. Sehnert, A.J., et al., *Cardiac troponin T is essential in sarcomere assembly and cardiac contractility*. Nat Genet, 2002. **31**(1): p. 106-10.
55. Liu, L., et al., *Combinatorial genetic replenishments in myocardial and outflow tract tissues restore heart function in tnnt2 mutant zebrafish*. Biol Open, 2019. **8**(12).
56. Isogai, S., et al., *Angiogenic network formation in the developing vertebrate trunk*. Development, 2003. **130**(21): p. 5281-90.

57. Watson, O., et al., *Blood flow suppresses vascular Notch signalling via *dll4* and is required for angiogenesis in response to hypoxic signalling*. *Cardiovasc Res*, 2013. **100**(2): p. 252-61.
58. Childs, S., et al., *Patterning of angiogenesis in the zebrafish embryo*. *Development*, 2002. **129**(4): p. 973-82.
59. Torres-Vazquez, J., et al., *Semaphorin-plexin signaling guides patterning of the developing vasculature*. *Dev Cell*, 2004. **7**(1): p. 117-23.
60. Embree, C.M., R. Abu-Alhasan, and G. Singh, *Features and factors that dictate if terminating ribosomes cause or counteract nonsense-mediated mRNA decay*. *J Biol Chem*, 2022. **298**(11): p. 102592.
61. Sharma, P., B.S. Sharma, and R.J. Verma, *CRISPR-based genome editing of zebrafish*. *Prog Mol Biol Transl Sci*, 2021. **180**: p. 69-84.
62. Gagnon, J.A., et al., *Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs*. *PLoS One*, 2014. **9**(5): p. e98186.
63. Uesugi, K., et al., *Different requirement for Rnd GTPases of R-Ras GAP activity of Plexin-C1 and Plexin-D1*. *J Biol Chem*, 2009. **284**(11): p. 6743-51.
64. Worzfeld, T., et al., *Genetic dissection of plexin signaling in vivo*. *Proc Natl Acad Sci U S A*, 2014. **111**(6): p. 2194-9.
65. Stratman, A.N., et al., *Interactions between mural cells and endothelial cells stabilize the developing zebrafish dorsal aorta*. *Development*, 2017. **144**(1): p. 115-127.
66. Campinho, P., et al., *Blood Flow Limits Endothelial Cell Extrusion in the Zebrafish Dorsal Aorta*. *Cell Rep*, 2020. **31**(2): p. 107505.
67. El-Brolosy, M.A., et al., *Genetic compensation triggered by mutant mRNA degradation*. *Nature*, 2019. **568**(7751): p. 193-197.
68. van der Zwaag, B., et al., *PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis*. *Dev Dyn*, 2002. **225**(3): p. 336-43.
69. Gitler, A.D., M.M. Lu, and J.A. Epstein, *PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development*. *Dev Cell*, 2004. **7**(1): p. 107-16.
70. Gu, C., et al., *Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins*. *Science*, 2005. **307**(5707): p. 265-8.
71. Zhang, Y., et al., *Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects*. *Dev Biol*, 2009. **325**(1): p. 82-93.
72. Zygumt, T., et al., *Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor *sFlt1**. *Dev Cell*, 2011. **21**(2): p. 301-14.
73. Sur, A., et al., *Single-cell analysis of shared signatures and transcriptional diversity during zebrafish development*. *bioRxiv*, 2023.
74. Sandireddy, R., et al., *Semaphorin 3E/PlexinD1 signaling is required for cardiac ventricular compaction*. *JCI Insight*, 2019. **4**(16).
75. Liu, X., et al., *Semaphorin 3G Provides a Repulsive Guidance Cue to Lymphatic Endothelial Cells via *Neuropilin-2/PlexinD1**. *Cell Rep*, 2016. **17**(9): p. 2299-2311.
76. Britto, D.D., et al., *Plexin D1 negatively regulates zebrafish lymphatic development*. *Development*, 2022. **149**(21).
77. Carretero-Ortega, J., et al., *GIPC proteins negatively modulate PlexinD1 signaling during vascular development*. *Elife*, 2019. **8**.
78. Dekker, R.J., et al., *Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (*KLF2*)*. *Blood*, 2002. **100**(5): p. 1689-98.
79. Dekker, R.J., et al., *Endothelial *KLF2* links local arterial shear stress levels to the expression of vascular tone-regulating genes*. *Am J Pathol*, 2005. **167**(2): p. 609-18.
80. Groenendijk, B.C., et al., *Development-related changes in the expression of shear stress responsive genes *KLF-2*, *ET-1*, and *NOS-3* in the developing cardiovascular system of chicken embryos*. *Dev Dyn*, 2004. **230**(1): p. 57-68.
81. Lin, Z., et al., *Kruppel-like factor 2 (*KLF2*) regulates endothelial thrombotic function*. *Circ Res*, 2005. **96**(5): p. e48-57.
82. Wang, N., et al., *Shear stress regulation of Kruppel-like factor 2 expression is flow pattern-specific*. *Biochem Biophys Res Commun*, 2006. **341**(4): p. 1244-51.
83. Sangwung, P., et al., **KLF2* and *KLF4* control endothelial identity and vascular integrity*. *JCI Insight*, 2017. **2**(4): p. e91700.

84. Wang, L., et al., *A blood flow-dependent klf2a-NO signaling cascade is required for stabilization of hematopoietic stem cell programming in zebrafish embryos*. *Blood*, 2011. **118**(15): p. 4102-10.
85. Novodvorsky, P., et al., *klf2ash317 Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes*. *PLoS One*, 2015. **10**(10): p. e0141611.
86. Stratman, A.N., et al., *Chemokine mediated signalling within arteries promotes vascular smooth muscle cell recruitment*. *Commun Biol*, 2020. **3**(1): p. 734.
87. Heckel, E., et al., *Oscillatory Flow Modulates Mechanosensitive klf2a Expression through trpv4 and trpp2 during Heart Valve Development*. *Curr Biol*, 2015. **25**(10): p. 1354-61.
88. Corti, P., et al., *Interaction between alk1 and blood flow in the development of arteriovenous malformations*. *Development*, 2011. **138**(8): p. 1573-82.
89. Tsaryk, R., et al., *Shear stress switches the association of endothelial enhancers from ETV/ETS to KLF transcription factor binding sites*. *Sci Rep*, 2022. **12**(1): p. 4795.
90. Fujita, M., et al., *Assembly and patterning of the vascular network of the vertebrate hindbrain*. *Development*, 2011. **138**(9): p. 1705-15.
91. Li, X., et al., *Primary cilia mediate Klf2-dependant Notch activation in regenerating heart*. *Protein Cell*, 2020. **11**(6): p. 433-445.
92. Sur, A., et al., *Single-cell analysis of shared signatures and transcriptional diversity during zebrafish development*. *Dev Cell*, 2023. **58**(24): p. 3028-3047 e12.
93. Rasouli, S.J., et al., *The flow responsive transcription factor Klf2 is required for myocardial wall integrity by modulating Fgf signaling*. *Elife*, 2018. **7**.
94. Renz, M., et al., *Regulation of beta1 integrin-Klf2-mediated angiogenesis by CCM proteins*. *Dev Cell*, 2015. **32**(2): p. 181-90.
95. Rodel, C.J., et al., *Blood Flow Suppresses Vascular Anomalies in a Zebrafish Model of Cerebral Cavernous Malformations*. *Circ Res*, 2019. **125**(10): p. e43-e54.
96. Yang, X., et al., *Release of STK24/25 suppression on MEKK3 signaling in endothelial cells confers cerebral cavernous malformation*. *JCI Insight*, 2023. **8**(5).
97. Kettleborough, R.N., et al., *A systematic genome-wide analysis of zebrafish protein-coding gene function*. *Nature*, 2013. **496**(7446): p. 494-7.
98. Masuda, H., et al., *Increase in endothelial cell density before artery enlargement in flow-loaded canine carotid artery*. *Arteriosclerosis*, 1989. **9**(6): p. 812-23.
99. Udan, R.S., T.J. Vadakkan, and M.E. Dickinson, *Dynamic responses of endothelial cells to changes in blood flow during vascular remodeling of the mouse yolk sac*. *Development*, 2013. **140**(19): p. 4041-50.
100. Roman, B.L., et al., *Disruption of acvr11 increases endothelial cell number in zebrafish cranial vessels*. *Development*, 2002. **129**(12): p. 3009-19.
101. Laux, D.W., et al., *Circulating Bmp10 acts through endothelial Alk1 to mediate flow-dependent arterial quiescence*. *Development*, 2013. **140**(16): p. 3403-12.
102. Watson, E.C., et al., *Apoptosis regulates endothelial cell number and capillary vessel diameter but not vessel regression during retinal angiogenesis*. *Development*, 2016. **143**(16): p. 2973-82.
103. Kidoya, H., et al., *Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis*. *EMBO J*, 2008. **27**(3): p. 522-34.
104. Poduri, A., et al., *Endothelial cells respond to the direction of mechanical stimuli through SMAD signaling to regulate coronary artery size*. *Development*, 2017. **144**(18): p. 3241-3252.
105. Gifre-Renom, L. and E.A.V. Jones, *Vessel Enlargement in Development and Pathophysiology*. *Front Physiol*, 2021. **12**: p. 639645.
106. Klems, A., et al., *The GEF Trio controls endothelial cell size and arterial remodeling downstream of Vegf signaling in both zebrafish and cell models*. *Nat Commun*, 2020. **11**(1): p. 5319.
107. Kondrychyn, I., et al., *Marcksl1 modulates endothelial cell mechanoresponse to haemodynamic forces to control blood vessel shape and size*. *Nat Commun*, 2020. **11**(1): p. 5476.
108. Lyons, S.E., et al., *A nonsense mutation in zebrafish gata1 causes the bloodless phenotype in vlad tepes*. *Proc Natl Acad Sci U S A*, 2002. **99**(8): p. 5454-9.
109. Belele, C.L., et al., *Differential requirement for Gata1 DNA binding and transactivation between primitive and definitive stages of hematopoiesis in zebrafish*. *Blood*, 2009. **114**(25): p. 5162-72.
110. Chow, R.W., et al., *Cardiac forces regulate zebrafish heart valve delamination by modulating Nfat signaling*. *PLoS Biol*, 2022. **20**(1): p. e3001505.
111. Iida, A., et al., *Metalloprotease-dependent onset of blood circulation in zebrafish*. *Curr Biol*, 2010. **20**(12): p. 1110-6.

112. Levic, D.S., et al., *Knock-in tagging in zebrafish facilitated by insertion into non-coding regions*. Development, 2021. **148**(19).
113. Kiener, T.K., I. Sleptsova-Friedrich, and W. Hunziker, *Identification, tissue distribution and developmental expression of tjp1/zo-1, tjp2/zo-2 and tjp3/zo-3 in the zebrafish, Danio rerio*. Gene Expr Patterns, 2007. **7**(7): p. 767-76.
114. Blum, Y., et al., *Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrafish embryo*. Dev Biol, 2008. **316**(2): p. 312-22.
115. Herwig, L., et al., *Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo*. Curr Biol, 2011. **21**(22): p. 1942-8.
116. Fadeev, A., et al., *Tight Junction Protein 1a regulates pigment cell organisation during zebrafish colour patterning*. Elife, 2015. **4**.
117. Yu, J.A., et al., *Single-cell analysis of endothelial morphogenesis in vivo*. Development, 2015. **142**(17): p. 2951-61.
118. Boon, R.A., et al., *KLF2-induced actin shear fibers control both alignment to flow and JNK signaling in vascular endothelium*. Blood, 2010. **115**(12): p. 2533-42.
119. Lagendijk, A.K., et al., *Live imaging molecular changes in junctional tension upon VE-cadherin in zebrafish*. Nat Commun, 2017. **8**(1): p. 1402.
120. Santoro, M.M., G. Pesce, and D.Y. Stainier, *Characterization of vascular mural cells during zebrafish development*. Mech Dev, 2009. **126**(8-9): p. 638-49.
121. Whitesell, T.R., et al., *An alpha-smooth muscle actin (acta2/alphasma) zebrafish transgenic line marking vascular mural cells and visceral smooth muscle cells*. PLoS One, 2014. **9**(3): p. e90590.
122. Ando, K., et al., *Clarification of mural cell coverage of vascular endothelial cells by live imaging of zebrafish*. Development, 2016. **143**(8): p. 1328-39.
123. Slegtenhorst, B.R., et al., *A Mechano-Activated Cell Reporter System as a Proxy for Flow-Dependent Endothelial Atheroprotection*. SLAS Discov, 2018. **23**(8): p. 869-876.
124. Blazeski, A., et al., *Engineering microvascular networks using a KLF2 reporter to probe flow-dependent endothelial cell function*. bioRxiv, 2023.
125. Sano, H., et al., *Control of vessel diameters mediated by flow-induced outward vascular remodeling in vitro*. Biofabrication, 2020. **12**(4): p. 045008.
126. Haase, K., et al., *Physiologic flow-conditioning limits vascular dysfunction in engineered human capillaries*. Biomaterials, 2022. **280**: p. 121248.
127. Kisanuki, Y.Y., et al., *Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo*. Dev Biol, 2001. **230**(2): p. 230-42.
128. Bi-Lin, K.W., et al., *Critical role of the BAF chromatin remodeling complex during murine neural crest development*. PLoS Genet, 2021. **17**(3): p. e1009446.
129. Cibi, D.M., et al., *Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure*. Cell Rep, 2020. **33**(3): p. 108288.
130. Cibi, D.M., et al., *Neural crest-specific deletion of Rbfox2 in mice leads to craniofacial abnormalities including cleft palate*. Elife, 2019. **8**.
131. McGrath, K.E., et al., *Circulation is established in a stepwise pattern in the mammalian embryo*. Blood, 2003. **101**(5): p. 1669-76.
132. Ji, R.P., et al., *Onset of cardiac function during early mouse embryogenesis coincides with entry of primitive erythroblasts into the embryo proper*. Circ Res, 2003. **92**(2): p. 133-5.
133. Phoon, C.K., O. Aristizabal, and D.H. Turnbull, *Spatial velocity profile in mouse embryonic aorta and Doppler-derived volumetric flow: a preliminary model*. Am J Physiol Heart Circ Physiol, 2002. **283**(3): p. H908-16.
134. Phoon, C.K., O. Aristizabal, and D.H. Turnbull, *40 MHz Doppler characterization of umbilical and dorsal aortic blood flow in the early mouse embryo*. Ultrasound Med Biol, 2000. **26**(8): p. 1275-83.
135. Srinivasan, S., et al., *Noninvasive, in utero imaging of mouse embryonic heart development with 40-MHz echocardiography*. Circulation, 1998. **98**(9): p. 912-8.
136. Sakurai, A., et al., *Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras*. Mol Cell Biol, 2010. **30**(12): p. 3086-98.
137. Wang, Y., et al., *Structural basis for activation and non-canonical catalysis of the Rap GTPase activating protein domain of plexin*. Elife, 2013. **2**: p. e01279.
138. Tata, A., et al., *An image-based RNAi screen identifies SH3BP1 as a key effector of Semaphorin 3E-PlexinD1 signaling*. J Cell Biol, 2014. **205**(4): p. 573-90.

139. Shang, G., et al., *Structure analyses reveal a regulated oligomerization mechanism of the PlexinD1/GIPC/myosin VI complex*. *Elife*, 2017. **6**.
140. Movassagh, H., et al., *Chemorepellent Semaphorin 3E Negatively Regulates Neutrophil Migration In Vitro and In Vivo*. *J Immunol*, 2017. **198**(3): p. 1023-1033.
141. Choi, Y.I., et al., *PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla*. *Immunity*, 2008. **29**(6): p. 888-98.
142. Rademacher, S., et al., *Metalloprotease-mediated cleavage of PlexinD1 and its sequestration to actin rods in the motoneuron disease spinal muscular atrophy (SMA)*. *Hum Mol Genet*, 2017. **26**(20): p. 3946-3959.
143. Paudel, R., L. Fusi, and M. Schmidt, *The MEK5/ERK5 Pathway in Health and Disease*. *Int J Mol Sci*, 2021. **22**(14).
144. Su, V.L. and D.A. Calderwood, *Signalling through cerebral cavernous malformation protein networks*. *Open Biol*, 2020. **10**(11): p. 200263.
145. Kumar, A., et al., *p53 impairs endothelial function by transcriptionally repressing Kruppel-Like Factor 2*. *Arterioscler Thromb Vasc Biol*, 2011. **31**(1): p. 133-41.
146. Kumar, A., et al., *Transcriptional repression of Kruppel like factor-2 by the adaptor protein p66shc*. *FASEB J*, 2009. **23**(12): p. 4344-52.
147. Pouillet, N., et al., *Mechanical instabilities of aorta drive blood stem cell production: a live study*. *Cell Mol Life Sci*, 2020. **77**(17): p. 3453-3464.
148. Amodeo, A.A. and J.M. Skotheim, *Cell-Size Control*. *Cold Spring Harb Perspect Biol*, 2016. **8**(4): p. a019083.
149. Nakajima, H. and N. Mochizuki, *Flow pattern-dependent endothelial cell responses through transcriptional regulation*. *Cell Cycle*, 2017. **16**(20): p. 1893-1901.
150. Sugden, W.W. and T.E. North, *Making Blood from the Vessel: Extrinsic and Environmental Cues Guiding the Endothelial-to-Hematopoietic Transition*. *Life (Basel)*, 2021. **11**(10).
151. Fukushima, Y., et al., *Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice*. *J Clin Invest*, 2011. **121**(5): p. 1974-85.
152. Kim, J., et al., *Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism*. *Genes Dev*, 2011. **25**(13): p. 1399-411.
153. Suda, K., et al., *Therapeutic potential of semaphorin 3E for the treatment of choroidal neovascularization*. *Invest Ophthalmol Vis Sci*, 2014. **55**(8): p. 4700-6.
154. Maruyama, K., et al., *Semaphorin3E-PlexinD1 signaling in coronary artery and lymphatic vessel development with clinical implications in myocardial recovery*. *iScience*, 2021. **24**(4): p. 102305.
155. Yu, R., et al., *Vascular Sema3E-Plexin-D1 Signaling Reactivation Promotes Post-stroke Recovery through VEGF Downregulation in Mice*. *Transl Stroke Res*, 2022. **13**(1): p. 142-159.
156. Vieira, J.R., et al., *Endothelial PlexinD1 signaling instructs spinal cord vascularization and motor neuron development*. *Neuron*, 2022. **110**(24): p. 4074-4089 e6.
157. Martins, L.F., et al., *Motor neurons use push-pull signals to direct vascular remodeling critical for their connectivity*. *Neuron*, 2022. **110**(24): p. 4090-4107 e11.
158. Olfert, I.M., et al., *Advances and challenges in skeletal muscle angiogenesis*. *Am J Physiol Heart Circ Physiol*, 2016. **310**(3): p. H326-36.
159. Dumas, S.J., et al., *Phenotypic diversity and metabolic specialization of renal endothelial cells*. *Nat Rev Nephrol*, 2021. **17**(7): p. 441-464.
160. Sun, M., et al., *PLXND1-mediated calcium dyshomeostasis impairs endocardial endothelial autophagy in atrial fibrillation*. *Front Physiol*, 2022. **13**: p. 960480.
161. Paolini, A., et al., *Mechanosensitive Notch-Dll4 and Klf2-Wnt9 signaling pathways intersect in guiding valvulogenesis in zebrafish*. *Cell Rep*, 2021. **37**(1): p. 109782.
162. Goddard, L.M., et al., *Hemodynamic Forces Sculpt Developing Heart Valves through a KLF2-WNT9B Paracrine Signaling Axis*. *Dev Cell*, 2017. **43**(3): p. 274-289 e5.
163. George, R.M., et al., *Single cell evaluation of endocardial Hand2 gene regulatory networks reveals HAND2-dependent pathways that impact cardiac morphogenesis*. *Development*, 2023. **150**(3).
164. Zhang, Y., et al., *Genetic reporter for live tracing fluid flow forces during cell fate segregation in mouse blastocyst development*. *Cell Stem Cell*, 2023. **30**(8): p. 1110-1123 e9.
165. Xia, J., et al., *Semaphorin-Plexin Signaling Controls Mitotic Spindle Orientation during Epithelial Morphogenesis and Repair*. *Dev Cell*, 2015. **33**(3): p. 299-313.

166. Singh, H. and J.D. Aplin, *Endometrial apical glycoproteomic analysis reveals roles for cadherin 6, desmoglein-2 and plexin b2 in epithelial integrity*. Mol Hum Reprod, 2015. **21**(1): p. 81-94.
167. Ta-Shma, A., et al., *Isolated truncus arteriosus associated with a mutation in the plexin-D1 gene*. Am J Med Genet A, 2013. **161A**(12): p. 3115-20.
168. Zhou, W.Z., et al., *Association of PLXND1 with a novel subtype of anomalous pulmonary venous return*. Hum Mol Genet, 2022. **31**(9): p. 1443-1452.
169. Guimier, A., et al., *Biallelic alterations in PLXND1 cause common arterial trunk and other cardiac malformations in humans*. Hum Mol Genet, 2023. **32**(3): p. 353-356.
170. Theis, J.L., et al., *CELSR1 Risk Alleles in Familial Bicuspid Aortic Valve and Hypoplastic Left Heart Syndrome*. Circ Genom Precis Med, 2022. **15**(2): p. e003523.
171. Degenhardt, K., et al., *Rapid 3D phenotyping of cardiovascular development in mouse embryos by micro-CT with iodine staining*. Circ Cardiovasc Imaging, 2010. **3**(3): p. 314-22.
172. Justice, A.E., et al., *Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution*. Nat Genet, 2019. **51**(3): p. 452-469.
173. Liang, C., C. Gu, and N. Wang, *Retinal Vascular Caliber in Coronary Heart Disease and Its Risk Factors*. Ophthalmic Res, 2023. **66**(1): p. 151-163.
174. Cheung, C.Y., et al., *A deep-learning system for the assessment of cardiovascular disease risk via the measurement of retinal-vessel calibre*. Nat Biomed Eng, 2021. **5**(6): p. 498-508.
175. Cook, I.O. and J. Chung, *Contemporary Medical Management of Peripheral Arterial Disease*. Cardiovasc Drugs Ther, 2023.
176. Bae, E., et al., *Renoprotective Effect of KLF2 on Glomerular Endothelial Dysfunction in Hypertensive Nephropathy*. Cells, 2022. **11**(5).
177. Zhong, F., et al., *Reduced Kruppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy*. Kidney Int, 2015. **87**(2): p. 382-95.
178. Sugihara, K., et al., *Comparisons between retinal vessel calibers and various optic disc morphologic parameters with different optic disc appearances: The Glaucoma Stereo Analysis Study*. PLoS One, 2021. **16**(7): p. e0250245.
179. Dewhirst, M.W. and T.W. Secomb, *Transport of drugs from blood vessels to tumour tissue*. Nat Rev Cancer, 2017. **17**(12): p. 738-750.
180. Yang, T. and J.R. Terman, *14-3-3epsilon couples protein kinase A to semaphorin signaling and silences plexin RasGAP-mediated axonal repulsion*. Neuron, 2012. **74**(1): p. 108-21.
181. Arrenberg, A.B., et al., *Optogenetic control of cardiac function*. Science, 2010. **330**(6006): p. 971-4.
182. Hagio, H., et al., *Optogenetic manipulation of neuronal and cardiomyocyte functions in zebrafish using microbial rhodopsins and adenylyl cyclases*. Elife, 2023. **12**.
183. Kopp, R., et al., *Chronic reduction in cardiac output induces hypoxic signaling in larval zebrafish even at a time when convective oxygen transport is not required*. Physiol Genomics, 2010. **42A**(1): p. 8-23.
184. Kugler, E., et al., *The effect of absent blood flow on the zebrafish cerebral and trunk vasculature*. Vasc Biol, 2021. **3**(1): p. 1-16.
185. Gore, A.V., et al., *Rspo1/Wnt signaling promotes angiogenesis via Vegfc/Vegfr3*. Development, 2011. **138**(22): p. 4875-86.
186. Lord, S.J., et al., *SuperPlots: Communicating reproducibility and variability in cell biology*. J Cell Biol, 2020. **219**(6).
187. Traver, D., et al., *Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants*. Nat Immunol, 2003. **4**(12): p. 1238-46.
188. Kwan, K.M., et al., *The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs*. Dev Dyn, 2007. **236**(11): p. 3088-99.
189. Villefranc, J.A., J. Amigo, and N.D. Lawson, *Gateway compatible vectors for analysis of gene function in the zebrafish*. Dev Dyn, 2007. **236**(11): p. 3077-87.
190. Shen, B., et al., *Generation of gene-modified mice via Cas9/RNA-mediated gene targeting*. Cell Res, 2013. **23**(5): p. 720-3.
191. Yamaguchi, N., et al., *Rear traction forces drive adherent tissue migration in vivo*. Nat Cell Biol, 2022. **24**(2): p. 194-204.
192. Hamm, M.J., B.C. Kirchmaier, and W. Herzog, *Sema3d controls collective endothelial cell migration by distinct mechanisms via Nrp1 and PlxnD1*. J Cell Biol, 2016. **215**(3): p. 415-430.
193. Montoya-Zegarra, J.A., et al., *AutoTube: a novel software for the automated morphometric analysis of vascular networks in tissues*. Angiogenesis, 2019. **22**(2): p. 223-236.

194. Montague, T.G., et al., *CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing*. Nucleic Acids Res, 2014. **42**(Web Server issue): p. W401-7.
195. Moreno-Mateos, M.A., et al., *CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo*. Nat Methods, 2015. **12**(10): p. 982-8.
196. Schindelin, J., et al., *Fiji: an open-source platform for biological-image analysis*. Nat Methods, 2012. **9**(7): p. 676-82.
197. Schneider, C.A., W.S. Rasband, and K.W. Eliceiri, *NIH Image to ImageJ: 25 years of image analysis*. Nat Methods, 2012. **9**(7): p. 671-5.
198. MathWorks, *MATLAB release: R2021a*. The MathWorks Inc., 2021.
199. Hill, J.T., et al., *Poly peak parser: Method and software for identification of unknown indels using sanger sequencing of polymerase chain reaction products*. Dev Dyn, 2014. **243**(12): p. 1632-6.
200. Brinkman, E.K., et al., *Easy quantitative assessment of genome editing by sequence trace decomposition*. Nucleic Acids Res, 2014. **42**(22): p. e168.
201. Bradford, Y.M., et al., *Zebrafish information network, the knowledgebase for Danio rerio research*. Genetics, 2022. **220**(4).
202. Karlsson, J., J. von Hofsten, and P.E. Olsson, *Generating transparent zebrafish: a refined method to improve detection of gene expression during embryonic development*. Mar Biotechnol (NY), 2001. **3**(6): p. 522-7.
203. Chen, M.B., et al., *On-chip human microvasculature assay for visualization and quantification of tumor cell extravasation dynamics*. Nat Protoc, 2017. **12**(5): p. 865-880.
204. Hajal, C., et al., *Engineered human blood-brain barrier microfluidic model for vascular permeability analyses*. Nat Protoc, 2022. **17**(1): p. 95-128.
205. Offeddu, G.S., et al., *Microheart: A microfluidic pump for functional vascular culture in microphysiological systems*. J Biomech, 2021. **119**: p. 110330.
206. Garcia-Cardena, G., et al., *Biomechanical activation of vascular endothelium as a determinant of its functional phenotype*. Proc Natl Acad Sci U S A, 2001. **98**(8): p. 4478-85.
207. Jao, L.E., S.R. Wentz, and W. Chen, *Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system*. Proc Natl Acad Sci U S A, 2013. **110**(34): p. 13904-9.
208. Katzen, F., *Gateway((R)) recombinational cloning: a biological operating system*. Expert Opin Drug Discov, 2007. **2**(4): p. 571-89.
209. Rafiq, M., et al., *Expression of recombinant human ceruloplasmin--an absolute requirement for splicing signals in the expression cassette*. FEBS Lett, 1997. **407**(2): p. 132-6.
210. Chatterjee, S., et al., *The role of post-transcriptional RNA processing and plasmid vector sequences on transient transgene expression in zebrafish*. Transgenic Res, 2010. **19**(2): p. 299-304.
211. Distel, M., M.F. Wullimann, and R.W. Koster, *Optimized Gal4 genetics for permanent gene expression mapping in zebrafish*. Proc Natl Acad Sci U S A, 2009. **106**(32): p. 13365-70.
212. Schek, N., C. Cooke, and J.C. Alwine, *Definition of the upstream efficiency element of the simian virus 40 late polyadenylation signal by using in vitro analyses*. Mol Cell Biol, 1992. **12**(12): p. 5386-93.
213. Turner, D.L. and H. Weintraub, *Expression of achaete-scute homolog 3 in Xenopus embryos converts ectodermal cells to a neural fate*. Genes Dev, 1994. **8**(12): p. 1434-47.
214. Kim, J.H., et al., *High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice*. PLoS One, 2011. **6**(4): p. e18556.
215. Grzegorski, S.J., et al., *Natural variability of Kozak sequences correlates with function in a zebrafish model*. PLoS One, 2014. **9**(9): p. e108475.
216. Gibson, D.G., et al., *Enzymatic assembly of DNA molecules up to several hundred kilobases*. Nat Methods, 2009. **6**(5): p. 343-5.
217. Kikuta, H. and K. Kawakami, *Transient and stable transgenesis using tol2 transposon vectors*. Methods Mol Biol, 2009. **546**: p. 69-84.
218. Isogai, S., M. Horiguchi, and B.M. Weinstein, *The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development*. Dev Biol, 2001. **230**(2): p. 278-301.
219. Legland, D., I. Arganda-Carreras, and P. Andrey, *MorphoLibJ: integrated library and plugins for mathematical morphology with ImageJ*. Bioinformatics, 2016. **32**(22): p. 3532-3534.